Astrazeneca PLC 6-K, filed Oct 30, 2026
Astrazeneca PLC (AZN)
6-K
2026-10-30
For: 2026-10-30
View Original
Added on
October 30, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on October 30, 2026.
AstraZeneca reported 9M 2026 total revenue up 7% at constant exchange rates and Core EPS up 14%, supported by double-digit growth in Oncology, R&I and Rare Disease. AI summary
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of October 2026
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F X Form 40-F __
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule
101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
______
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1.
3rd Quarter Results
30
October 2026
AstraZeneca
results: 9M and Q3 2026
Continued strong commercial
performance and 12 positive Phase III programme readouts in the
year to date
http://www.rns-pdf.londonstockexchange.com/rns/0827B_1-2026-10-29.pdf
Revenue
and EPS summary
|
|
9M 2026
|
%
Change
|
Q3 2026
|
%
Change
|
||
|
|
$m
|
Actual
|
CER1
|
$m
|
Actual
|
CER
|
|
-
Product Sales
|
43,962
|
7
|
5
|
15,066
|
5
|
5
|
|
- Alliance Revenue
|
2,806
|
33
|
32
|
1,107
|
36
|
36
|
|
Product
Revenue
|
46,768
|
8
|
6
|
16,173
|
7
|
7
|
|
Collaboration
Revenue
|
113
|
22
|
23
|
36
|
>3x
|
>3x
|
|
Total Revenue
|
46,881
|
8
|
7
|
16,209
|
7
|
7
|
|
Reported EPS ($)
|
5.62
|
10
|
11
|
2.02
|
23
|
26
|
|
Core2 EPS ($)
|
8.00
|
14
|
14
|
2.79
|
17
|
19
|
Key performance elements for 9M 2026
(Growth numbers at constant exchange rates)
*
Total Revenue up
7%, with double-digit growth in Oncology, R&I and Rare Disease
offsetting headwinds from Farxiga
and Brilinta loss of exclusivity and volume-based
procurement in China
*
Core Operating
profit and Core EPS increased 14%
*
47 approvals in
major regions since Q4 2025 results, including first approvals for
four new medicines (Etcamah, Baxfendy, Klygefa and Amlypave)
*
First Phase III
data for three NMEs (tozorakimab, efzimfotase alfa and sonesitatug
vedotin)
Pascal Soriot, Chief Executive Officer, AstraZeneca,
said:
“In
the first nine months we saw strong commercial momentum with total
revenue up 7% and Core EPS up 14%, driven by our diverse therapy
areas and global presence. We have had approvals for four new
medicines and reported 12 positive Phase III programme
readouts with a collective peak year revenue potential well in
excess of ten billion dollars. Our rich series of upcoming readouts
in 2027 has a potential of more than twenty billion
dollars.
With
multiple potential blockbuster assets in late-stage development and
transformative technologies scaling rapidly, we are on track to
deliver our 2030 ambition and to sustain growth through the next
decade.”
AstraZeneca
reconfirms Total Revenue and Core EPS guidance3 for FY 2026 at CER,
based on the average foreign exchange rates through
2025.
Total Revenue is expected to increase by a mid-to-high single-digit
percentage
Core EPS is expected to increase by a low double-digit percentage
The
Core Tax rate is expected to be between 18-22%
If
foreign exchange rates for October 2026 to December 2026 were to
remain at the average rates seen in September 2026, it is
anticipated that Total Revenue in FY 2026 would benefit from a low
single-digit percentage positive impact (unchanged) compared to the
performance at CER, and Core EPS growth would be broadly similar
(unchanged) to the growth at CER.
Results
highlights
Table
1: Milestones achieved since the prior results
announcement
Phase
III and other registrational data readouts
|
Medicine
|
Trial
|
Indication
|
Event
|
|
Enhertu
|
DESTINY-Lung04
|
1L
HER2m NSCLC
|
Primary
endpoint met
|
|
Etcamah
|
SERENA-4
|
1L HR+
HER2- advanced breast cancer
|
Primary
endpoint not met
|
|
Imfinzi + tarlatamab
|
DeLLphi-305
|
1L
ES-SCLC (maintenance)
|
Primary
endpoint met
|
|
Lynparza
|
MONO-OLA1
|
1L
BRCAwt ovarian cancer
|
Dual
primary endpoints met
|
|
Tagrisso + Orpathys
|
SAFFRON
|
2L+
EGFRm, MET-overexpressed
and/or amplified NSCLC
|
Primary
endpoint met
|
|
Tagrisso + Orpathys
|
SANOVO
|
1L
EGFRm, MET-overexpressed
NSCLC
|
Primary
endpoint met
|
|
volrustomig
|
eVOLVE-Lung02
|
1L
PD-L1 <50% mNSCLC
|
Discontinued due to
futility
|
|
Tezspire
|
CROSSING
|
Eosinophilic esophagitis
|
Co-primary
endpoints met
|
|
Ultomiris
|
AWAKE
|
Delayed Graft Function
|
Discontinued due to
lack of efficacy
|
Regulatory
approvals
|
Medicine
|
Trial
|
Indication
|
Region
|
|
Datroway
|
TROPION-Breast02
|
1L TNBC
for patients where immunotherapy is not an option
|
EU, JP,
CN
|
|
Enhertu
|
DESTINY-Breast09
|
1L
HER2+ mBC
|
EU, JP,
CN
|
|
Enhertu
|
DESTINY-Breast05
|
High-risk
HER2+ early breast cancer (post-neoadjuvant)
|
EU,
CN
|
|
Enhertu
|
DESTINY-PanTumor02
|
HER2+
solid tumours
|
CN
|
|
Etcamah
|
SERENA-6
|
ESR1m HR+ HER2- 1L advanced breast cancer
|
US
|
|
Imfinzi
|
POTOMAC
|
NMIBC
|
JP
|
|
Breztri
|
KALOS /
LOGOS
|
Asthma
|
EU,
JP
|
|
Klygefa (gefurulimab)
|
PREVAIL
|
Generalised
myasthenia gravis
|
JP
|
|
Amlypave (anselamimab)
|
CARES
|
Kappa
light chain amyloidosis
|
JP
|
|
Ultomiris
|
I
CAN
|
IgAN
|
US
|
|
Ultomiris
|
ALXN1210-PNH-323
|
PNH
|
CN
|
Regulatory
submissions or acceptances* in major regions
|
Medicine
|
Trial
|
Indication
|
Region
|
|
Calquence
|
AMPLIFY
|
1L CLL
(fixed duration)
|
CN
|
|
Imfinzi
|
VOLGA
|
MIBC
not candidates for cisplatin
|
US, EU,
JP
|
|
Truqap
|
CAPItello-281
|
PTEN-deficient
mHSPC
|
CN
|
|
tozorakimab
|
OBERON
/ TITANIA / PROSPERO
|
COPD
|
US,
JP
|
|
Ultomiris
|
I
CAN
|
IgAN
|
CN
|
|
Ultomiris
|
ALXN1210-TMA-314
|
HSCT-TMA
(paediatric)
|
US
|
|
efzimfotase
alfa
|
MULBERRY
/ CHESTNUT / HICKORY
|
HPP
|
US, EU,
CN
|
* US, EU and China regulatory entries in this table denote filing
acceptance
Other pipeline updates
For
recent trial starts and anticipated timings of key trial readouts,
please refer to the Clinical Trials Appendix document in the
financial results section of the AstraZeneca investor relations
website: www.astrazeneca.com/investor-relations.html
Table
2: Key elements of financial performance: Q3 2026
|
For the quarter
|
Reported
|
Change
|
Core
|
Change
|
|
||
|
ended 30 September
|
$m
|
Act
|
CER
|
$m
|
Act
|
CER
|
|
|
Product
Revenue
|
16,173
|
7
|
7
|
16,173
|
7
|
7
|
*
See
Tables 3, 7, 23, 24 and 25 for further details of Product Revenue,
Product Sales and Alliance Revenue
|
|
Collaboration
Revenue
|
36
|
>3x
|
>3x
|
36
|
>3x
|
>3x
|
*
See
Tables 4 and 26 for further details of Collaboration
Revenue
|
|
Total
Revenue
|
16,209
|
7
|
7
|
16,209
|
7
|
7
|
*
See
Tables 5 and 6 for Total Revenue by Therapy Area and by
region
|
|
Gross
Margin (%)
|
82
|
-
|
+1pp
|
82
|
-
|
+1pp
|
+ Positive product
mix effects
– Pricing headwinds,
including those driven by loss of exclusivity and VBP in
China
*
Variations in Gross
Margin can be expected between periods due to various factors,
including fluctuations in foreign exchange rates, product
seasonality and
Collaboration Revenue
|
|
R&D
expense
|
3,894
|
6
|
7
|
3,645
|
3
|
3
|
*
Core
R&D: 22% of Total Revenue (23% for 9M 2026)
+ Increasing number
of trials, and patients in those trials
+ Investments in
transformative technologies
+ Addition of
R&D projects from business development
Positive data
readouts for high value pipeline opportunities that have ungated
large late-stage trials
*
Variations in the
year-on-year change in R&D expenses can be expected between
periods due to the phasing of trial starts and
completions
|
|
SG&A
expense
|
5,108
|
-
|
-
|
3,909
|
2
|
2
|
*
Core
SG&A: 24% of Total Revenue (25% for 9M 2026)
+ Investment to
support ongoing and future launches
*
Variations in the
year-on-year change in SG&A expenses can be expected between
periods due to the phasing of product launches and other
programmes
|
|
Other
operating income and expense4
|
277
|
>3x
|
>3x
|
277
|
>2x
|
>2x
|
+ Various partner
milestones and royalties
+ Disposal of
Zoryve interest
|
|
Operating
profit
|
4,387
|
22
|
26
|
5,855
|
17
|
20
|
+ See commentary
above on Gross Margin, R&D, SG&A
|
|
Operating
Margin (%)
|
27
|
+3pp
|
+4pp
|
36
|
+3pp
|
+4pp
|
and Other operating
income and expense
|
|
Net
finance expense
|
410
|
17
|
22
|
371
|
22
|
27
|
+ Lower interest
income on short-term deposits and higher interest expense on
short-term borrowings
+ Higher discount
unwind on lease liabilities, principally due to the new strategic
R&D centre in Massachusetts, US
– Reported Net
finance expense benefitted from a lower discount unwind on
contingent consideration liabilities
|
|
Tax
rate (%)
|
21
|
-1pp
|
-1pp
|
21
|
-
|
-1pp
|
*
Variations in the
tax rate can be expected between periods
|
|
EPS
($)
|
2.02
|
23
|
26
|
2.79
|
17
|
19
|
+ See commentary
above
|
For dollar values in this table, the unit of change is percent. For
Gross Margin, Operating Margin and Tax rate, the unit of change is
percentage points (pp).
In the table above, R&D expense, SG&A expense and Net
finance expense are displayed as positive numbers. The plus and
minus symbols next to comments denote the directional impact of the
item being discussed. For example, a plus symbol next to a comment
about an R&D item indicates that the item increased R&D
expenditure relative to the prior year period.
Corporate and
business
development
Summit
Therapeutics
In
October AstraZeneca completed a $2bn equity investment in Summit
Therapeutics Inc. (Summit). The investment gives AstraZeneca rights
equivalent to approximately 12.0% of Summit Therapeutics’
outstanding common stock, or approximately 10.6% on a fully diluted
basis.
AstraZeneca
and Summit entered into a clinical collaboration agreement to
evaluate sonesitatug vedotin in combination with Summit’s
PD-1/VEGF bispecific antibody ivonescimab. The two companies also
entered into a clinical collaboration with Daiichi Sankyo to
evaluate Datroway in
combination with ivonescimab.
AstraZeneca
and Summit intend to enter into an additional agreement initiating
a global development programme combining other AstraZeneca cancer
medicines, including additional ADCs, with
ivonescimab.
Kendall Square
R&D Centre
In
October, AstraZeneca formally opened its new global strategic
R&D centre, in Kendall Square, Cambridge, Massachusetts. The
state-of-the-art facility builds on the Company’s existing
presence in Boston and Cambridge, Massachusetts and will be home to
nearly 2,000 world-class researchers and scientists.
Reshaping
for Sustainable Growth
AstraZeneca
is in a catalyst rich period with more than 180 pipeline projects
driving its next wave of growth and scientific innovation. To
capitalise on this opportunity, the Company has initiated the
Reshaping for Sustainable Growth (RSG) programme to create
additional capacity to invest behind its industry-leading pipeline
and transformative technologies. Over the next three years, the
programme will redeploy resources and strengthen capabilities
across AstraZeneca’s existing business and therapy areas. The
RSG programme is expected to cost up to $2.0bn in one-time
restructuring costs and deliver $1.5bn in annualised pre-tax
run-rate benefits. The savings generated will continue to be
reinvested back into the Company, principally in the pipeline. The
Company anticipates activities to be essentially complete by the
end of 2029.
insitro
In
October, AstraZeneca entered into a strategic drug discovery
collaboration and licensing agreement with insitro. Using advanced
AI systems, the collaboration will identify novel drug targets and
advance the design of new therapeutics for MASH and
cardiomyopathies.
Under
the terms of the agreement, insitro will receive an upfront payment
of $40m, and is also eligible for up to approximately $1.46bn in
potential development and commercial milestones, plus potential
single digit royalties based on global commercial sales.
AstraZeneca will have exclusive worldwide rights to advance
selected programmes identified under the
collaboration.
Dizal
Pharmaceutical Co
In
August, AstraZeneca completed the license agreement with Dizal
Pharmaceutical Co., Ltd for Zegfrovy, which is approved in the US
and China for the 2nd-line treatment of adult patients with locally
advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
See Interim Financial Statements, Note 5, for further
details.
Sustainability highlights
AstraZeneca
ranked fifth on TIME Magazine’s 2026 World’s Best
Companies list - its highest position to date and the top ranking
among pharmaceutical companies - based on sustainability
transparency, revenue growth, and employee
satisfaction.
Reporting calendar
The
Company intends to publish its FY and Q4 2026 results on 9
February 2027.
Conference call
A conference call and webcast for investors and analysts will begin
today, 30 October 2026, at 14:30 UK time. Details can be
accessed via astrazeneca.com.
Notes
1.
Constant exchange
rates. The differences between Actual Change and CER Change are due
to foreign exchange movements between periods in 2026 vs. 2025. CER
financial measures are not accounted for according to generally
accepted accounting principles (GAAP) because they remove the
effects of currency movements from Reported results.
2.
Core financial
measures are adjusted to exclude certain items. The differences
between Reported and Core measures are primarily due to costs
relating to the amortisation of intangibles, impairments, legal
settlements and restructuring charges. A full reconciliation
between Reported EPS and Core EPS is provided in Tables 10 and 11
in the Financial Performance section of this document.
3.
The Company is
unable to provide guidance on a Reported basis because it cannot
reliably forecast material elements of the Reported results,
including any fair value adjustments arising on acquisition-related
liabilities, intangible asset impairment charges and legal
settlement provisions. Please refer to the Cautionary statements
section regarding forward-looking statements at the end of this
announcement.
4.
Income from
disposals of assets and businesses, where the Group does not retain
a significant ongoing economic interest, is recorded in Other
operating income and expense in the Group’s financial
statements.
Revenue
drivers
Table
3: Product Revenue (PR) by medicine
|
|
9M 2026
|
|
% Change
|
Q3 2026
|
|
%
Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Tagrisso
|
5,862
|
13
|
10
|
8
|
2,087
|
13
|
12
|
12
|
|
Imfinzi
|
5,538
|
12
|
28
|
27
|
1,990
|
12
|
24
|
26
|
|
Calquence
|
3,009
|
6
|
18
|
16
|
1,065
|
7
|
16
|
16
|
|
Lynparza
|
2,421
|
5
|
1
|
(2)
|
811
|
5
|
(3)
|
(3)
|
|
Enhertu
|
2,688
|
6
|
36
|
33
|
969
|
6
|
36
|
35
|
|
Zoladex
|
967
|
2
|
9
|
5
|
336
|
2
|
13
|
10
|
|
Truqap
|
641
|
1
|
30
|
29
|
210
|
1
|
9
|
9
|
|
Imjudo
|
263
|
1
|
4
|
4
|
103
|
1
|
23
|
25
|
|
Datroway
|
176
|
-
|
>4x
|
>4x
|
78
|
-
|
>3x
|
>3x
|
|
Etcamah
|
10
|
-
|
n/m
|
n/m
|
7
|
-
|
n/m
|
n/m
|
|
Other
Oncology
|
313
|
1
|
(3)
|
(4)
|
109
|
1
|
2
|
3
|
|
Oncology PR
|
21,888
|
47
|
18
|
16
|
7,765
|
48
|
17
|
17
|
|
Farxiga
|
5,603
|
12
|
(12)
|
(15)
|
1,605
|
10
|
(25)
|
(25)
|
|
Crestor
|
1,018
|
2
|
8
|
5
|
332
|
2
|
9
|
6
|
|
Lokelma
|
638
|
1
|
23
|
23
|
219
|
1
|
16
|
17
|
|
Seloken
|
519
|
1
|
11
|
6
|
182
|
1
|
14
|
9
|
|
Brilinta
|
261
|
1
|
(61)
|
(62)
|
75
|
-
|
(48)
|
(50)
|
|
Wainua
|
189
|
-
|
33
|
33
|
68
|
-
|
16
|
17
|
|
roxadustat
|
78
|
-
|
(66)
|
(68)
|
21
|
-
|
(73)
|
(74)
|
|
Baxfendy
|
12
|
-
|
n/m
|
n/m
|
9
|
-
|
n/m
|
n/m
|
|
Other
CVRM
|
298
|
1
|
(29)
|
(30)
|
92
|
1
|
(36)
|
(34)
|
|
Cardiovascular, Renal & Metabolism PR
|
8,616
|
18
|
(11)
|
(15)
|
2,603
|
16
|
(19)
|
(20)
|
|
Symbicort
|
2,084
|
4
|
(4)
|
(7)
|
666
|
4
|
(10)
|
(11)
|
|
Fasenra
|
1,655
|
4
|
14
|
13
|
602
|
4
|
13
|
14
|
|
Breztri
|
1,073
|
2
|
18
|
16
|
374
|
2
|
16
|
14
|
|
Tezspire
|
1,123
|
2
|
46
|
44
|
429
|
3
|
50
|
51
|
|
Saphnelo
|
615
|
1
|
27
|
27
|
235
|
1
|
31
|
32
|
|
Pulmicort
|
378
|
1
|
6
|
2
|
109
|
1
|
18
|
16
|
|
Airsupra
|
129
|
-
|
12
|
13
|
42
|
-
|
(7)
|
(4)
|
|
Other
R&I
|
211
|
-
|
(9)
|
(11)
|
61
|
-
|
3
|
1
|
|
Respiratory & Immunology PR
|
7,268
|
16
|
12
|
10
|
2,518
|
16
|
11
|
11
|
|
Beyfortus
|
427
|
1
|
(10)
|
(10)
|
233
|
1
|
(1)
|
(2)
|
|
FluMist
|
172
|
-
|
30
|
29
|
146
|
1
|
20
|
20
|
|
Other
ID
|
136
|
-
|
(38)
|
(41)
|
44
|
-
|
(24)
|
(25)
|
|
Infectious Disease PR
|
735
|
2
|
(11)
|
(12)
|
423
|
3
|
2
|
1
|
|
Ultomiris
|
4,016
|
9
|
16
|
16
|
1,432
|
9
|
17
|
19
|
|
Soliris
|
1,076
|
2
|
(25)
|
(26)
|
298
|
2
|
(35)
|
(35)
|
|
Strensiq
|
1,641
|
4
|
38
|
37
|
588
|
4
|
33
|
34
|
|
Koselugo
|
585
|
1
|
17
|
15
|
238
|
1
|
6
|
9
|
|
Other
Rare Disease
|
226
|
-
|
28
|
25
|
77
|
-
|
20
|
24
|
|
Rare Disease PR
|
7,544
|
16
|
12
|
11
|
2,633
|
16
|
9
|
10
|
|
Other
Medicines PR
|
717
|
1
|
(5)
|
(6)
|
231
|
1
|
(3)
|
(3)
|
|
Product Revenue
|
46,768
|
100
|
8
|
6
|
16,173
|
100
|
7
|
7
|
|
|
|
|
|
|
|
|
|
|
|
Alliance Revenue included above:
|
|
|
|
|
|
|
|
|
|
Enhertu
|
1,670
|
4
|
29
|
27
|
612
|
4
|
34
|
34
|
|
Tezspire
|
614
|
1
|
36
|
35
|
242
|
1
|
44
|
44
|
|
Beyfortus
|
279
|
1
|
11
|
11
|
156
|
1
|
11
|
10
|
|
Datroway
|
164
|
-
|
>4x
|
>4x
|
71
|
-
|
>2x
|
>2x
|
|
Other
royalty revenue
|
76
|
-
|
8
|
8
|
25
|
-
|
8
|
4
|
|
Other
Alliance Revenue
|
3
|
-
|
(16)
|
(16)
|
1
|
-
|
3
|
3
|
|
Alliance Revenue
|
2,806
|
6
|
33
|
32
|
1,107
|
7
|
36
|
36
|
Table
4: Collaboration Revenue
|
|
9M 2026
|
|
% Change
|
Q3 2026
|
|
%
Change
|
||
|
|
$m
|
|
Actual
|
CER
|
$m
|
|
Actual
|
CER
|
|
Farxiga: sales milestones
|
80
|
|
(2)
|
(1)
|
36
|
|
>6x
|
>7x
|
|
Crestor: sales milestones
|
32
|
|
n/m
|
n/m
|
-
|
|
n/m
|
n/m
|
|
Others
|
1
|
|
(89)
|
(87)
|
-
|
|
n/m
|
n/m
|
|
Collaboration Revenue
|
113
|
|
22
|
23
|
36
|
|
>3x
|
>3x
|
Table
5: Total Revenue by Therapy Area
|
|
9M 2026
|
|
% Change
|
Q3 2026
|
|
%
Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
Oncology
|
21,889
|
47
|
18
|
16
|
7,765
|
48
|
17
|
17
|
|
- Cardiovascular, Renal & Metabolism
|
8,728
|
19
|
(11)
|
(14)
|
2,639
|
16
|
(18)
|
(18)
|
|
- Respiratory & Immunology
|
7,268
|
16
|
12
|
10
|
2,518
|
16
|
11
|
11
|
|
- Infectious Disease
|
735
|
2
|
(11)
|
(12)
|
423
|
3
|
2
|
1
|
|
BioPharmaceuticals
|
16,731
|
36
|
(2)
|
(5)
|
5,580
|
34
|
(5)
|
(6)
|
|
Rare
Disease
|
7,544
|
16
|
12
|
11
|
2,633
|
16
|
9
|
10
|
|
Other
Medicines
|
717
|
2
|
(6)
|
(8)
|
231
|
1
|
(5)
|
(5)
|
|
Total Revenue
|
46,881
|
100
|
8
|
7
|
16,209
|
100
|
7
|
7
|
Table
6: Total Revenue by region
|
|
9M 2026
|
|
% Change
|
Q3 2026
|
|
%
Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
US
|
19,789
|
42
|
7
|
7
|
6,899
|
43
|
5
|
5
|
|
- Emerging Markets ex. China
|
7,085
|
15
|
11
|
8
|
2,276
|
14
|
4
|
4
|
|
- China
|
5,430
|
12
|
3
|
(3)
|
1,920
|
12
|
9
|
3
|
|
Emerging
Markets
|
12,515
|
27
|
7
|
3
|
4,196
|
26
|
6
|
4
|
|
Europe
|
10,528
|
22
|
15
|
10
|
3,706
|
23
|
11
|
12
|
|
Established
RoW
|
4,049
|
9
|
4
|
7
|
1,408
|
9
|
4
|
11
|
|
Total Revenue
|
46,881
|
100
|
8
|
7
|
16,209
|
100
|
7
|
7
|
Table
7: Product Revenue by region
|
|
9M 2026
|
|
% Change
|
Q3 2026
|
|
%
Change
|
||
|
|
$m
|
% Total
|
Actual
|
CER
|
$m
|
% Total
|
Actual
|
CER
|
|
US
|
19,788
|
42
|
7
|
7
|
6,899
|
43
|
5
|
5
|
|
- Emerging Markets ex. China
|
7,085
|
15
|
11
|
8
|
2,276
|
14
|
4
|
4
|
|
- China
|
5,430
|
12
|
3
|
(3)
|
1,920
|
12
|
9
|
3
|
|
Emerging
Markets
|
12,515
|
27
|
7
|
3
|
4,196
|
26
|
6
|
4
|
|
Europe
|
10,528
|
23
|
15
|
10
|
3,706
|
23
|
11
|
12
|
|
Established
RoW
|
3,937
|
8
|
3
|
7
|
1,372
|
8
|
3
|
9
|
|
Total Product Revenue
|
46,768
|
100
|
8
|
6
|
16,173
|
100
|
7
|
7
|
Total Revenue by Medicine
Oncology
Tagrisso
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Strong
demand growth across indications and key regions, positioned as
backbone across all stages of EGFRm NSCLC. Leading combination in 1L
NSCLC (FLAURA2)
|
||
|
US
|
2,467
|
11
|
11
|
|
*
Robust
underlying demand
|
|
|
Emerging
Markets
|
1,656
|
10
|
6
|
|
*
More
competitive environment in China in a slowing EGFRm TKI market
|
|
|
Europe
|
1,169
|
13
|
8
|
|
|
|
|
Established
RoW
|
570
|
(3)
|
1
|
|
*
Recent
competitor entrant
|
|
|
Total
|
5,862
|
10
|
8
|
|
|
|
Imfinzi
|
9M 2026
$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Strong
demand growth across all regions from existing indications and new
launches
|
||
|
US
|
3,128
|
26
|
26
|
|
*
Demand
growth led by new GI and GU launches (MATTERHORN,
NIAGARA)
|
|
|
Emerging
Markets
|
627
|
35
|
33
|
|
*
Strong
growth in GI (HIMALAYA, TOPAZ) including new launches
(MATTERHORN)
|
|
|
Europe
|
1,210
|
38
|
31
|
|
*
Early
momentum for new lung (ADRIATIC), GI (MATTERHORN) and GU (NIAGARA)
launches
|
|
|
Established
RoW
|
573
|
17
|
23
|
|
*
Demand
growth from new launches across GYN (DUO-E), GU (NIAGARA) and lung
(ADRIATIC, AEGEAN)
|
|
|
Total
|
5,538
|
28
|
27
|
|
|
|
Calquence
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Sustained BTKi
leadership in front-line CLL with launch momentum across finite use
for 1L CLL (AMPLIFY) and 1L MCL (ECHO)
|
||
|
US
|
1,982
|
16
|
16
|
|
*
Strong
demand growth from ongoing leadership in front-line CLL BTKi
market
|
|
|
Emerging
Markets
|
214
|
31
|
25
|
|
|
|
|
Europe
|
690
|
21
|
16
|
|
*
Rapid
AMPLIFY adoption across key markets and further expansion in 1L
MCL
|
|
|
Established
RoW
|
123
|
6
|
6
|
|
|
|
|
Total
|
3,009
|
18
|
16
|
|
|
|
Lynparza
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Global
leadership in mature first-generation PARPi market, volume growth
offset by pricing in some markets
|
||
|
US
|
1,012
|
(4)
|
(4)
|
|
*
Demand
growth offset by gross to net adjustments
|
|
|
Emerging
Markets
|
507
|
4
|
(1)
|
|
*
Affected by generic
competition in China and VBP implementation
|
|
|
Europe
|
710
|
6
|
1
|
|
*
Stable
volumes
|
|
|
Established
RoW
|
192
|
-
|
3
|
|
|
|
|
Total
|
2,421
|
1
|
(2)
|
|
|
|
Enhertu
Combined
sales of Enhertu, recorded
by Daiichi Sankyo and AstraZeneca, amounted to $4,675m in 9M 2026
(9M 2025: $3,575m). US in-market sales, recorded by Daiichi Sankyo,
amounted to $2,329m in 9M 2026 (9M 2025: $1,734m). For periods up
to and including Q3 2025, AstraZeneca’s mid-single-digit
percentage royalty on Daiichi Sankyo's sales in Japan is recorded
in Europe; from Q4 2025 this royalty is recorded in Established
RoW.
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Standard-of-care in
HER2-positive (DESTINY-Breast03) and HER2-low (DESTINY-Breast04)
metastatic breast cancer, early uptake in other
cancers
|
||
|
US
|
1,122
|
35
|
35
|
|
*
Ongoing
adoption in 1L HER2-positive breast cancer (DESTINY-Breast09) and
early uptake following early breast cancer launches
(DESTINY-Breast05, DESTINY-Breast11)
|
|
|
Emerging
Markets
|
849
|
44
|
41
|
|
*
Broader
adoption and improved access across regions
|
|
|
Europe
|
596
|
22
|
15
|
|
*
Further
demand growth in chemotherapy naïve HER2-low breast
cancer
|
|
|
Established
RoW
|
121
|
91
|
90
|
|
|
|
|
Total
|
2,688
|
36
|
33
|
|
|
|
Other
Oncology medicines
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Zoladex
|
968
|
9
|
5
|
|
*
Growth
across Emerging Markets, partly offset by divestment of rights in
Japan in May 2026
|
|
|
Truqap
|
641
|
30
|
29
|
|
*
Achieved peak share
in US in second-line biomarker-altered metastatic breast cancer; Q3
2026 affected by US destocking following bottle to blister
transition
|
|
|
Imjudo
|
263
|
4
|
4
|
|
*
Continued GI
(HIMALAYA) growth ex-US and China launch in Q3 2026, offset by
lower demand in some markets
|
|
|
Datroway
|
176
|
>4x
|
>4x
|
|
*
Continued uptake in
breast cancer with early adoption in 1L TNBC (TROPION-Breast02),
and EGFRm later-line lung
cancer
*
Combined global
sales by AstraZeneca and Daiichi Sankyo: $413m (9M 2025:
$115m)
|
|
|
Etcamah
|
10
|
n/m
|
n/m
|
|
*
Initial
uptake following US launch (SERENA-6)
|
|
|
Other
Oncology
|
313
|
(3)
|
(4)
|
|
*
Generic
erosion across markets
|
|
Other Oncology includes $14m of Total Revenue from Orpathys,
partnered with HUTCHMED and $3m of Total Revenue from
Zegfrovy
BioPharmaceuticals
– Cardiovascular, Renal & Metabolism
Farxiga
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Growth
impacted by US LoE and China VBP
|
||
|
US
|
795
|
(36)
|
(36)
|
|
*
Multiple generics
launched in Q2 2026
|
|
|
Emerging
Markets
|
2,200
|
(16)
|
(21)
|
|
*
Affected by generic
competition, VBP implementation in China in Q1 2026 and
unfavourable tender timing in some Emerging Markets
|
|
|
Europe
|
2,385
|
11
|
6
|
|
*
Demand
growth partly offset by generic entry in the UK in Q3
2025
|
|
|
Established
RoW
|
303
|
(27)
|
(25)
|
|
*
Generic
T2D entry in Japan in Q4 2025. Milestone receipts in Q1 and Q3
2026
|
|
|
Total
|
5,683
|
(12)
|
(15)
|
|
|
|
Other
CVRM medicines
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Crestor
|
1,050
|
11
|
8
|
|
*
Growth
driven by Emerging Markets
|
|
|
Lokelma
|
638
|
23
|
23
|
|
*
Growth
in all major regions
|
|
|
Seloken
|
519
|
11
|
6
|
|
*
Growth
driven by Emerging Markets
|
|
|
Brilinta
|
261
|
(61)
|
(62)
|
|
*
Decline
driven by generic entry in the US and Europe in Q2
2025
|
|
|
Wainua
|
189
|
33
|
33
|
|
*
Demand
growth in ATTR-PN and geographic expansion
|
|
|
roxadustat
|
78
|
(66)
|
(68)
|
|
*
Affected by generic
competition in China and VBP implementation in Q1 2026
|
|
|
Baxfendy
|
12
|
n/m
|
n/m
|
|
*
US
launch in hypertension in Q2 2026
|
|
|
Other
CVRM
|
298
|
(29)
|
(30)
|
|
*
Generic
erosion
|
|
BioPharmaceuticals
- Respiratory & Immunology
Symbicort
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Market
leader in ICS/LABA class with increasing generic
competition
|
||
|
US
|
772
|
(15)
|
(15)
|
|
*
Demand
for brand offset by price pressure; launch of additional generic in
market
|
|
|
Emerging
Markets
|
653
|
5
|
1
|
|
|
|
|
Europe
|
425
|
5
|
(1)
|
|
|
|
|
Established
RoW
|
234
|
(5)
|
(7)
|
|
|
|
|
Total
|
2,084
|
(4)
|
(7)
|
|
|
|
Fasenra
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Continued severe
eosinophilic asthma market share leadership in IL-5 class, further
fuelled by accelerated EGPA and HES indication
launches
|
||
|
US
|
949
|
7
|
7
|
|
*
Strong
demand with IL-5 class leadership
|
|
|
Emerging
Markets
|
149
|
85
|
78
|
|
*
Strong
China uptake post Q1 2026 NRDL listing with growth in other key
markets
|
|
|
Europe
|
389
|
11
|
5
|
|
*
Increased
leadership in severe eosinophilic asthma partially offset by
pricing
|
|
|
Established
RoW
|
168
|
26
|
30
|
|
*
Strong
growth supported by EGPA in Japan
|
|
|
Total
|
1,655
|
14
|
13
|
|
|
|
Breztri
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Fastest
growing medicine within the expanding FDC triple class
(ICS/LABA/LAMA)
|
||
|
US
|
479
|
4
|
4
|
|
*
Share
growth in COPD and asthma launch offset by gross-to-net
adjustments
|
|
|
Emerging
Markets
|
329
|
38
|
31
|
|
*
Market
share leadership within FDC triple class in China
|
|
|
Europe
|
183
|
34
|
28
|
|
*
Sustained growth
from market share gains
|
|
|
Established
RoW
|
82
|
19
|
21
|
|
|
|
|
Total
|
1,073
|
18
|
16
|
|
|
|
Tezspire
Combined
sales of Tezspire, recorded
by Amgen and AstraZeneca, amounted to $1,876m in 9M 2026 (9M 2025:
$1,321m).
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Sustained demand
growth in severe asthma with launch momentum across multiple
markets
|
||
|
US
|
614
|
36
|
35
|
|
*
Continued strong
demand growth in severe asthma and launch of CRSwNP
|
|
|
Emerging
Markets
|
64
|
>2x
|
>2x
|
|
*
Strong
continued uptake
|
|
|
Europe
|
322
|
56
|
49
|
|
*
Continued
new-to-brand leadership across multiple markets and market
growth
|
|
|
Established
RoW
|
123
|
43
|
48
|
|
|
|
|
Total
|
1,123
|
46
|
44
|
|
|
|
Other
R&I medicines
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Saphnelo
|
615
|
27
|
27
|
|
*
Strong
demand growth fuelled by s.c. launches
|
|
|
Pulmicort
|
378
|
6
|
2
|
|
*
Emerging Market
growth offset by pressure in Europe and Established
RoW
|
|
|
Airsupra
|
129
|
12
|
13
|
|
*
US
demand volume growth partially offset by pricing
pressures
|
|
|
Other R&I
|
211
|
(9)
|
(11)
|
|
|
|
BioPharmaceuticals
– Infectious Disease
Total Revenue
for Beyfortus reflects the
sum of Product Sales from AstraZeneca’s sales of manufactured
product to Sanofi, and Alliance Revenue from AstraZeneca’s
share of gross profits and royalties on sales in major markets
outside the US.
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Beyfortus
|
427
|
(10)
|
(10)
|
|
*
Partner’s
adjustment of inventory levels
|
|
|
FluMist
|
172
|
30
|
29
|
|
|
|
|
Other
ID
|
136
|
(38)
|
(41)
|
|
*
Other
includes Synagis, which
declined due to competition from Beyfortus
|
|
Rare
Disease
Ultomiris
Total
Revenue for Ultomiris
includes sales of Voydeya,
which is approved as an add-on treatment to Ultomiris and Soliris for the ~20‑30% of PNH patients
who experience clinically significant EVH.
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Growth
due to patient demand, both naïve to C5 medicines and
conversion from Soliris
across all indications (gMG, NMOSD, aHUS and PNH)
|
||
|
US
|
2,190
|
12
|
12
|
|
*
Demand
growth across indications, including within the competitive gMG and
PNH landscapes
|
|
|
Emerging
Markets
|
306
|
73
|
73
|
|
*
Expansion into new
markets and growth in patient demand
|
|
|
Europe
|
915
|
19
|
14
|
|
*
Demand
growth following launches; competition in gMG and PNH
|
|
|
Established
RoW
|
605
|
11
|
16
|
|
*
Continued
conversion and strong patient demand
|
|
|
Total
|
4,016
|
16
|
16
|
|
|
|
Soliris
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Decline
driven by conversion of patients to Ultomiris across all indications
|
||
|
US
|
595
|
(30)
|
(30)
|
|
*
Affected by
biosimilar pressure
|
|
|
Emerging
Markets
|
311
|
(5)
|
(7)
|
|
|
|
|
Europe
|
89
|
(44)
|
(47)
|
|
*
Affected by
biosimilar pressure in PNH and aHUS
|
|
|
Established
RoW
|
81
|
(24)
|
(23)
|
|
|
|
|
Total
|
1,076
|
(25)
|
(26)
|
|
|
|
Strensiq
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
*
Growth
driven by continued HPP patient demand
|
||
|
US
|
1,332
|
40
|
40
|
|
|
|
|
Emerging
Markets
|
111
|
81
|
67
|
|
*
Continued launches
in new markets
|
|
|
Europe
|
104
|
17
|
12
|
|
*
Demand
growth and improved access following new launches
|
|
|
Established
RoW
|
94
|
11
|
17
|
|
|
|
|
Total
|
1,641
|
38
|
37
|
|
|
|
Other
Rare Disease medicines
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Koselugo
|
585
|
17
|
15
|
|
*
Continued patient
demand, strong uptake following launch of adult indication. Q3 2026
benefitted from tender order timing in Emerging
Markets
|
|
|
Other
Rare Disease
|
226
|
28
|
25
|
|
*
Other
Rare Disease medicines include Kanuma, and Beyonttra (JP only)
|
|
Other
Medicines
|
9M 2026$m
|
Total
Revenue
|
% Change
Actual CER
|
|
|
||
|
Other
Medicines
|
717
|
(6)
|
(8)
|
|
*
Generic
erosion
|
|
R&D
progress
This
section covers R&D events and milestones that occurred from 27
July 2026 up to and including 29 October 2026. A comprehensive view
of AstraZeneca's pipeline of medicines in human trials can be found
in the latest Clinical Trials Appendix, available on
AstraZeneca’s investor relations
webpage. The Clinical Trials Appendix includes tables with
details of the ongoing clinical trials for AstraZeneca medicines
and new molecular entities in the pipeline.
Oncology
AstraZeneca
presented new data across its diverse portfolio of cancer medicines
at two major medical congresses since the prior results
announcement: the IASLC 2026 World Conference on Lung Cancer (WCLC)
and the European Society for Medical Oncology Congress 2026 (ESMO).
Across the two meetings, more than 140 abstracts were presented
featuring 27 approved and potential new medicines including 38 oral
presentations.
Datroway
|
Approval
EU
|
TROPION-Breast02
July
2026
|
*
As monotherapy for
the 1st-line treatment of adult patients with unresectable or
metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor
therapy.
|
|
Approval
JP
|
TROPION-Breast02
September
2026
New disclosure
|
*
1st-line treatment
of unresectable or metastatic TNBC not candidates for PD-1/PD-L1
inhibitor therapy.
|
|
Approval
CN
|
TROPION-Breast02
October
2026
New disclosure
|
*
For
patients with unresectable or metastatic TNBC not candidates for
PD-1/PD-L1 inhibitor therapy.
|
Enhertu
|
Phase III readout and data presentation
WCLC
|
DESTINY-Lung04
August/September
2026
|
*
Positive results
from the DESTINY-Lung04 Phase III trial showed Enhertu reduced the risk of disease
progression or death by 37% versus pembrolizumab plus chemotherapy
(HR 0.63; 95% CI 0.50-0.79; p<0.0001) as 1st-line treatment of
patients with unresectable, locally advanced or metastatic
HER2-mutant non-squamous NSCLC. Median PFS was 14.3 months with
Enhertu compared to 8.3
months for pembrolizumab plus chemotherapy.
|
|
Approval
CN
|
DESTINY-Breast09
August
2026
New disclosure
|
*
In
combination with pertuzumab for the 1st-line treatment of adult
patients with unresectable or metastatic HER2-positive breast
cancer.
|
|
Approval
EU
|
DESTINY-Breast09
September
2026
|
*
In
combination with pertuzumab for the 1st-line treatment of adult
patients with unresectable or metastatic HER2-positive breast
cancer.
|
|
Approval
JP
|
DESTINY-Breast09
September
2026
New disclosure
|
*
In combination with
pertuzumab for the 1st-line treatment of adult patients with
unresectable or metastatic HER2-positive breast
cancer.
|
|
Approval
CN
|
DESTINY-Breast05
October
2026
New disclosure
|
*
Adjuvant treatment
of adult patients with HER2-positive early breast cancer who have
residual invasive disease after neoadjuvant taxane and
trastuzumab-based treatment.
|
|
Approval
CN
|
DESTINY-PanTumor02, DESTINY-Lung01, DESTINY-CRC02 and
DESTINY-PanTumor03
October
2026
New disclosure
|
*
Unresectable or
metastatic solid tumours with HER2 expression (IHC 3+) who have
received prior treatment or have no satisfactory alternative
treatment options.
|
|
Approval
EU
|
DESTINY-Breast05
October
2026
|
*
As
monotherapy for the adjuvant treatment of adult patients with
resected HER2-positive breast cancer who have residual invasive
disease after neoadjuvant taxane-based and HER2-targeted
treatment.
|
Etcamah (camizestrant)
|
Approval
US
|
SERENA-6
September
2026
|
*
In
combination with a CDK4/6 inhibitor (abemaciclib, palbociclib or
ribociclib) for HR-positive, HER2-negative, locally advanced or
metastatic breast cancer upon detection of ESR1 mutation during aromatase
inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorised
test.
|
|
Phase III readout
|
SERENA-4
September
2026
|
*
The
SERENA-4 Phase III trial of Etcamah in combination with palbociclib
did not meet the primary endpoint of PFS, however a numerical
improvement was observed in the upfront 1st-line treatment of
patients with ER-positive, HER2-negative advanced breast cancer who
have not received any systemic treatment for advanced disease. The
trial evaluated the Etcamah
combination versus treatment with an aromatase inhibitor
(anastrozole) in combination with palbociclib.
|
Imfinzi
|
Approval
JP
|
POTOMAC
August
2026
New disclosure
|
*
In
combination with Bacillus Calmette-Guérin for the treatment of
adult patients with BCG-naïve, high-risk non-muscle-invasive
bladder cancer.
|
|
Phase III readout and data presentation
ESMO
|
DeLLphi-305
September/October
2026
|
*
Positive results
from the DeLLphi-305 Phase III trial showed Imfinzi plus tarlatamab reduced the
risk of death by 58% versus Imfinzi alone (HR 0.42; 95% CI
0.32-0.54; p<0.001) as 1st-line maintenance treatment for
patients with ES-SCLC who had not progressed following standard
induction treatment with Imfinzi plus platinum-etoposide
chemotherapy. Median OS was 21.1 months with Imfinzi plus tarlatamab compared to
12.7 months for Imfinzi
alone.
|
|
CHMP opinion
EU
|
Label update
September
2026
New disclosure
|
*
Recommended update
to the Imfinzi label
reducing the infusion time from 60 to 30 minutes.
|
|
Priority Review
US
|
VOLGA
September
2026
|
*
Perioperative
treatment with Imfinzi in
combination with neoadjuvant enfortumab vedotin for patients with
MIBC who are ineligible for or have declined cisplatin-based
chemotherapy.
|
|
Data presentation
ESMO
|
VOLGA
October
2026
|
*
Positive results
from a planned interim analysis of the VOLGA Phase III trial showed
perioperative Imfinzi plus
neoadjuvant enfortumab vedotin reduced the risk of disease
progression, recurrence, not undergoing surgery or death by 49%
versus radical cystectomy with or without approved adjuvant
treatment (EFS HR 0.51; 95% CI 0.38-0.67; p<0.0001) in patients
with MIBC who were ineligible for or had refused cisplatin-based
chemotherapy. Median EFS was not reached with the Imfinzi regimen compared to 12.1 months
for the comparator arm. For the key secondary endpoint of OS, the
Imfinzi regimen reduced the
risk of death by 42% (HR 0.58; 95% CI 0.40-0.83;
p=0.0027).
|
Lynparza
|
Phase III readout
|
MONO-OLA1
Q3
2026
New disclosure
|
*
Positive high-level
results from the MONO-OLA1 Phase III trial showed that both primary
endpoints were met, with Lynparza demonstrating statistically
significant improvements in PFS versus placebo in both the BRCAwt
HRD-positive and BRCAwt populations when used as 1st-line
maintenance treatment for patients with newly diagnosed high grade
serous or endometrioid ovarian cancer. The safety profile of
Lynparza observed in
MONO-OLA1 was generally consistent with its known profile.
AstraZeneca does not intend to progress with regulatory filings in
US, Europe, China or Japan given the increasing trend towards PARP
inhibitors being approved and used primarily in the BRCAm and
HRD-positive settings in 1L ovarian cancer, a population where
Lynparza +/- bevacizumab,
is already the established standard of care.
|
Tagrisso
|
Phase III readout and data presentation
ESMO
|
SAFFRON
August/October
2026
|
*
Positive results
from the SAFFRON Phase III trial showed Tagrisso plus Orpathys reduced the risk of disease
progression or death by 45% versus doublet platinum-based
chemotherapy (HR 0.55; 95% CI 0.42-0.72; p<0.001) in patients
with EGFRm locally advanced
or metastatic NSCLC with high levels of MET overexpression or
amplification who had progressed on prior treatment with
Tagrisso. Median PFS was
7.6 months with Tagrisso
plus Orpathys compared to
5.4 months for chemotherapy. For the key secondary endpoint of OS,
Tagrisso plus Orpathys reduced the risk of death by
32% (HR 0.68; 95% CI 0.50-0.91; p=0.010), extending median OS by
4.9 months (17.8 versus 12.9 months).
|
|
Phase III readout and data presentation
ESMO
|
SANOVO
September/October
2026
|
*
Positive results
from the SANOVO China-only Phase III trial showed Tagrisso plus Orpathys reduced the risk of disease
progression or death by 44% versus Tagrisso alone in the
intention-to-treat population (HR 0.56; 95% CI 0.43-0.74;
p<0.0001) and by 55% in the high MET (IHC 3+) population (HR
0.45; 95% CI 0.31-0.66; p<0.0001) in treatment-naïve
patients with EGFRm locally
advanced or metastatic NSCLC and MET overexpression. Median PFS was
24.9 months with Tagrisso
plus Orpathys compared to
13.8 months for Tagrisso
alone in the intention-to-treat population. For the secondary
endpoint of OS in the intention-to-treat population, Tagrisso plus Orpathys showed a very encouraging
clinical benefit versus Tagrisso alone (HR 0.48; 95% CI
0.33-0.68), with median OS of 44.5 months compared to 34.9
months.
|
|
Data presentation
WCLC
|
ADAURA
September
2026
|
*
Updated
exploratory results from the ADAURA Phase III trial showed
Tagrisso demonstrated a
sustained, clinically meaningful OS benefit at eight years compared
to placebo in the adjuvant treatment of patients with early-stage
(IB, II and IIIA) EGFRm
NSCLC after complete tumour resection, reducing the risk of death
by 47% in the primary population (Stage II-IIIA) (HR 0.53; 95% CI
0.38-0.75) and by 48% in the overall trial population (HR 0.52; 95%
CI 0.39-0.71).
|
Truqap
|
Regulatory update
EU
|
CAPItello-281
October
2026
New disclosure
|
*
Withdrawal of the
Type II variation application for Truqap in combination with abiraterone
for the treatment of PTEN-deficient metastatic hormone-sensitive
prostate cancer, based on the CAPItello-281 Phase III
trial.
|
sonesitatug
vedotin (sone-ve)
|
Data presentation
ESMO
|
CLARITY-Gastric01
October
2026
|
*
Positive results
from a planned interim analysis of the CLARITY-Gastric01 Phase III
trial showed sonesitatug vedotin reduced the risk of death by 53%
versus investigator’s choice of therapy (HR 0.47; 95% CI
0.36-0.62; p<0.001) in patients with 3rd- and later-line
CLDN18.2-positive advanced gastric, GEJ or oesophageal
adenocarcinoma. Median OS was 10.0 months with sonesitatug vedotin
compared to 5.0 months for investigator’s choice of therapy.
In the overall 2nd- and later-line trial population, sonesitatug
vedotin reduced the risk of death by 42% (HR 0.58; 95% CI
0.47-0.73; p<0.001); the other dual primary endpoint of PFS in
this population did not reach statistical
significance.
|
volrustomig
|
Phase III trial update
|
eVOLVE-Lung02
August
2026
|
*
The
eVOLVE-Lung02 Phase III trial of volrustomig in combination with
chemotherapy versus pembrolizumab and chemotherapy as 1st-line
treatment for patients with metastatic NSCLC whose tumours express
PD-L1 <50% has been discontinued, following an IDMC
recommendation that the combination was unlikely to meet either of
the dual primary endpoints of PFS or OS in the primary analysis
population of patients with PD-L1 negative tumours (<1%). The
other Phase III volrustomig trials continue as
planned.
|
BioPharmaceuticals
– Cardiovascular, Renal & Metabolism
Wainua
|
Data presentationESC
|
CARDIO-TTRansform
August 2026
|
*
Wainua in
patients with ATTR-CM did not meet the primary efficacy endpoint of
the composite outcome of CV mortality and recurrent CV clinical
events up to 140 weeks compared with placebo (rate ratio (RR) 0.89,
95% CI, 0.73-1.09, P=0.277). In a prespecified analysis,
Wainua reduced the risk of
CV death and recurrent CV events by 29% vs. placebo in
patients not receiving a stabiliser at baseline (RR
0.71, 95% CI, 0.54-0.93).
|
BioPharmaceuticals
– Respiratory & Immunology
Breztri (Trixeo)
|
Approval
EU
(Trixeo)
|
KALOS / LOGOS
September 2026
|
*
Maintenance
treatment of asthma in patients 12 years of age and older who are
not adequately controlled by a combination of a medium dose inhaled
corticosteroid and long-acting b₂-agonist.
|
|
Approval
JP
(Breztri)
|
KALOS / LOGOS
September 2026
New disclosure
|
*
For
bronchial asthma (when a combination of an inhaled corticosteroid,
a long-acting inhaled anticholinergic agent and a long-acting
inhaled b₂-agonist is necessary). The intended use population
includes both adults and children aged 12 years or
above.
|
|
Approval
US (Breztri)
|
NGP programme
October 2026
New disclosure
|
*
Breztri, already licensed for the
treatment of COPD in adults and asthma in patients 12 years of age
and older, has received approval in the US for the updated
formulation containing AstraZeneca’s next-generation
propellant with near-zero global warming potential.
|
Tezspire
|
Phase III readout and data presentation
UEGW
|
CROSSINGSeptember / October
2026
|
*
Positive results
from the CROSSING Phase III trial demonstrated that treatment with
Tezspire achieved
histologic remission for 64.8% (210mg dose) and 68.9% (420mg dose)
of patients at week 24, compared to 3.5% of patients on placebo
(p<0.001). Tezspire also
reduced the frequency and severity of dysphagia symptoms by 18.8
points (210mg dose; p=0.049) and 22.0 points (420mg dose,
p<0.001) from baseline vs. 14.7 on placebo, as measured by the
Dysphagia Symptom Questionnaire (DSQ) score, a patient-reported
outcome measure. Efficacy was sustained in both doses through week
52, as measured in key secondary endpoints.
|
tozorakimab
|
Data presentation
ERS
|
OBERON / TITANIA
September 2026
|
*
Positive results
from the OBERON and TITANIA Phase III trials demonstrated that
tozorakimab, administered once every four weeks, demonstrated a
reduction in moderate and severe COPD exacerbations in the primary
population of former smokers by 29% (OBERON) and 34% (TITANIA), and
in the overall population of current and former smokers by 30%
(OBERON) and 29% (TITANIA) compared with placebo while on inhaled
standard of care. In addition, based on a pooled analysis of OBERON
and TITANIA, patients on tozorakimab with a baseline blood
eosinophil count of less than 150 cells/uL achieved a 23% reduction
in moderate and severe exacerbations; patients at or above 150
achieved a 34% reduction; and patients at or above 300 achieved a
43% reduction.
|
|
Priority Review
US
|
OBERON / TITANIA / PROSPERO
August 2026
|
*
Add-on
maintenance treatment for adult patients with COPD.
|
|
Data presentationCHEST
|
PROSPEROOctober
2026
|
*
In the
PROSPERO long-term extension trial of OBERON and TITANIA,
tozorakimab demonstrated a numerical, but not statistically
significant, reduction in severe exacerbations (a different primary
endpoint than OBERON and TITANIA) in the primary endpoint
population of former smokers (21%; 0.26 vs 0.33 annualised rates;
RR 0.79 (95% CI 0.61,1.01) p=0.0587). There was a nominally
significant reduction in severe exacerbations in the overall
population of former and current smokers (27%; 0.26 vs 0.36
annualised rates; RR 0.73 (95% CI 0.58, 0.91) p=0.0046). Consistent
with the primary endpoint in the OBERON and TITANIA trials,
PROSPERO, in a secondary endpoint, showed continued tozorakimab
treatment maintained the reduction in moderate and severe COPD
exacerbations in former smokers and the overall population at 104
weeks. The safety and tolerability profile of tozorakimab through
104 weeks in PROSPERO was consistent with the profile observed in
the OBERON and TITANIA trials.
|
Rare
Disease
Amlypave (anselamimab)
|
Approval
JP
|
CARES
September 2026
|
*
For
systemic light chain (AL) amyloidosis (only in patients with
predominantly kappa immunoglobulin light chain).
|
efzimfotase
alfa
|
Data presentation
ASBMR
|
HICKORY
October 2026
|
*
In the
overall population, at week 25, efzimfotase alfa achieved a least
squares (LS) mean difference of 17.05 metres (p=0.1675) change from
baseline in the primary endpoint of 6MWT, compared to placebo. The
lack of statistical significance was largely due to
better-than-expected results observed in the adult-onset HPP
placebo group.
*
In a
combination of prespecified subgroups of adolescents and adults
with paediatric-onset HPP, efzimfotase alfa demonstrated nominally
significant and clinically meaningful benefits in the primary
endpoint of 6MWT, achieving an LS mean difference of 35.6 metres
(nominal p=0.0386) vs placebo at week 25, as well as the key
secondary endpoints of 30s-STS (LS mean difference vs placebo: 1.3;
nominal p=0.0384) and BPI-SF Pain Severity (LS mean difference vs
placebo: -1.0; nominal p=0.0260).
|
|
Priority Review
US
|
HICKORY/MULBERRY/CHESTNUT
September 2026
|
Patients with
hypophosphatasia aged ≥2 years.
|
Klygefa (gefurulimab)
|
Approval
JP
|
PREVAIL
September 2026
New disclosure
|
*
For
generalised myasthenia gravis (only for patients who are not
adequately responsive to steroids or nonsteroidal
immunosuppressants).
|
|
CHMP opinion
EU
|
PREVAIL
September
2026
|
*
Recommended as an
add-on to standard therapy for the treatment of generalised
myasthenia gravis (gMG) in adults who are anti-acetylcholine
receptor (AChR) antibody-positive.
|
Ultomiris
|
Approval
CN
|
ALXN1210-PNH-323
August
2026
New disclosure
|
*
For the
treatment of adult and paediatric patients one month of age and
older with paroxysmal nocturnal haemoglobinuria.
|
|
Phase III trial update
|
AWAKE
October
2026
New disclosure
|
*
AWAKE
Phase III clinical trial evaluating Ultomiris in adult kidney transplant
recipients who are at risk of delayed graft function has been
discontinued, following an IDMC recommendation that Ultomiris was unlikely to meet the
trial’s primary endpoint of time to freedom from dialysis
through 90 days post-transplant versus placebo. The safety profile
observed in this trial was consistent with the known profile of
Ultomiris, with no new
safety concerns identified.
|
|
Approval
US
|
I CAN
October
2026
|
*
For the
reduction of proteinuria in adults with primary immunoglobulin A
nephropathy who are at risk for disease progression.
|
|
Priority Review
US
|
ALXN1210-TMA-314
ALX-TMA-502
September
2026
New disclosure
|
*
Paediatric patients
with haematopoietic stem cell transplant-associated thrombotic
microangiopathy.
|
Sustainability
Sustainability
highlights
AstraZeneca
ranked fifth on TIME Magazine’s 2026 World’s Best
Companies list - its highest position to date and the top ranking
among pharmaceutical companies - based on sustainability
transparency, revenue growth, and employee
satisfaction.
At
Climate Week NYC, AstraZeneca’s delegation, led by Pam Cheng,
EVP Global Operations, IT and Chief Sustainability Officer, engaged
with more than 60 stakeholders, and advancing dialogues on
sustainable, equitable and resilient healthcare. The Company
announced the next phase of its flagship Young Health Programme in
partnership with UNICEF, bringing its total investment from
2010-2030 to more than $100 million. The programme, which supports
young people in underserved communities, aims to prevent
non-communicable diseases by activating young people to advance
health equity and address the health impacts of climate change in
more than 60 countries. Pam Cheng gave a live broadcast interview
on the Company’s sustainability action at the New York Stock
Exchange.
Climate
and nature
AstraZeneca
has successfully completed the transition of Breztri/Trixeo Aerosphere to its
next-generation propellant (NGP) with near-zero global warming
potential in 30 countries, following approvals in the UK, EU and
Australia. In the US, Breztri received regulatory approval as
the first inhaled respiratory medicine to use NGP. Regulatory
filings have also been submitted in China and Japan.
The
Company officially launched CARESA (CARe pathways Environmental
Sustainability Assessment) a free tool that helps healthcare
professionals model the potential environmental impact of patient
care pathways and explore choices that could improve health
outcomes for patients and the planet.
The
European Network on Climate & Health Education, supported by
AstraZeneca through the Sustainable Markets Initiative Health
Systems Task Force which Pascal Soriot chairs, has helped 61
medical schools integrate sustainability into medical training,
engaging over 3,000 faculty members and reaching 6,000 medical
students to date.
AstraZeneca
received the My Green Lab and International Institute for
Sustainable Laboratories (I2SL) 2026 Freezer Challenge Award for
the Biotech and Pharmaceutical sector for the third time. The
Freezer Challenge is a global initiative that promotes more
sustainable laboratory operations through improved freezer and cold
storage management, helping reduce energy use and improve
efficiency. In addition, in the UK, AstraZeneca maintained the
highest achievable rating, Level 4, in the NHS Evergreen
Sustainable Supplier Assessment for
2026–2027.
Health
equity
A new
report, Addressing Inequalities in COPD and Lung Cancer: A
Framework for Action, was launched to help policymakers and health
system leaders address inequalities in care. The report was
informed by a literature review and international expert input,
including from Brazil, Italy, Saudi Arabia, Spain and Vietnam, and
the London School of Economics (LSE Health).
In the
US, AstraZeneca held community engagement events in Baltimore and
Houston to increase awareness of lung health and improve
understanding of clinical research.
Through
Cancer Care Africa (CCA), AstraZeneca advanced patient support,
evidence generation and clinical capacity across several African
countries. This includes digitalising the ‘Sanady’
patient support programme in Morocco; generating evidence in Egypt
on the potential of AI-supported triage; publishing national lung
cancer registry data in Algeria; and strengthening respiratory care
capabilities in Kenya through training in pleural procedures,
bronchoscopy and endobronchial ultrasound.
Healthy
Heart Africa (HHA) partnered with Kenya’s Ministry of Health
to launch the country’s first National CKD Guidelines and the
second phase of the National CKD Registry. Since May 2025, HHA has
screened over 11,000 high-risk individuals across Kenya for CKD.
Uganda’s Ministry of Health launched HHA-supported CKD
Guidelines.
Health
systems resilience
AstraZeneca
continued to advance its work to strengthen health systems through
the Partnership for Health System Sustainability and Resilience
(PHSSR), which has now collaborated with 36 countries.
Policy
roadmaps on early action on NCDs were launched in seven countries,
convening government representatives, policymakers and patient
groups to help unlock system-level changes, including to advance
and accelerate screening programs, early detection capability and
sustainable funding for innovative medicines. In Q3, launches in
Spain and Greece convened government representatives, policymakers
and patient groups to unlock system-level change based on the
roadmap’s recommendations. Spain’s State Secretary for
Health spoke at the roadmap launch at the Congress of Deputies. In
France, PHSSR brought together more than 50 participants to discuss
health system sustainability and resilience, including the former
French Minister for Solidarity and Health.
PHSSR
also engaged stakeholders in Mexico on research recommendations,
and Germany’s Monitor Versorgungsforschung, a peer-reviewed
healthcare research journal, published an article examining the
PHSSR Synthesis Report and its comparison of eight advanced health
systems.
Operating and
financial review
Reporting
currency
All
narrative on growth and results in this section is based on actual
exchange rates, and financial figures are in US$ millions ($m),
unless stated otherwise.
Reporting
period
The
performance shown in this announcement covers the nine-month period
to 30 September 2026 ('9M 2026') compared to the nine-month period
to 30 September 2025 (‘9M 2025’), and the three-month
period to 30 September 2026 ('the quarter' or 'Q3 2026') compared
to the three-month period to 30 September 2025 (‘Q3
2025’), unless stated otherwise.
Non-GAAP
financial measures
Core
financial measures, EBITDA, Net debt, Core Tax rate and CER are
non-GAAP financial measures because they cannot be derived directly
from the Group's Condensed consolidated financial
statements.
Management
believes that these non-GAAP financial measures, when provided in
combination with Reported results, provide investors and analysts
with helpful supplementary information to better understand the
financial performance and position of the Group on a comparable
basis from period to period.
These
non-GAAP financial measures are not a substitute for, or superior
to, financial measures prepared in accordance with
GAAP.
Non-GAAP
financial measures (cont.)
Core
financial measures are adjusted to exclude certain significant
items:
–
Charges and
provisions related to our global restructuring programmes, which
includes charges that relate to the impact of restructuring
programmes on our capitalised manufacturing assets and IT
assets
–
Amortisation and
impairment of intangible assets, including impairment reversals but
excluding any charges relating to IT assets
–
Other specified
items, principally comprising acquisition-related costs and
credits, which include the imputed finance charges and fair value
movements relating to contingent consideration on business
combinations, imputed finance charges and remeasurement adjustments
on certain other payables arising from intangible asset
acquisitions, remeasurement adjustments relating to certain other
payables, debt items assumed from the Alexion acquisition and legal
settlements
–
The tax effects of
the adjustments above are excluded from the Core Tax
charge
Details
on the nature of Core financial measures are provided on page 53 of
the Annual Report and Form 20-F
Information 2025.
Reference
should be made to the Reconciliation of Reported to Core financial
measures table included in the Financial Performance section in
this announcement.
Definitions
Gross
Margin is defined as Gross Profit as a percentage of Total
Revenue.
EBITDA
is defined as Reported Profit before tax after adding back Net
finance expense, results from Joint ventures and associates and
charges for Depreciation, amortisation and impairment. Reference
should be made to the Reconciliation of Reported Profit before tax
to EBITDA included in the Financial Performance section in this
announcement.
Operating
Margin is defined as Operating profit as a percentage of Total
Revenue.
Net
debt is defined as Interest-bearing loans and borrowings and Lease
liabilities, net of Cash and cash equivalents, Other investments,
and Net derivative financial instruments. Reference should be made
to Note 3 'Net debt', included in the Notes to the Interim
financial statements in this announcement.
The
Company strongly encourages investors and analysts not to rely on
any single financial measure, but to review AstraZeneca's financial
statements, including the Notes thereto, and other available
Company reports, carefully and in their entirety.
Due to
rounding, the sum of a number of dollar values and percentages in
this announcement may not agree to totals.
Financial
performance
Table
8: Reported Profit and Loss
|
|
9M 2026
|
9M 2025
|
%
Change
|
Q3 2026
|
Q3 2025
|
%
Change
|
||
|
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
- Product Sales
|
43,962
|
41,035
|
7
|
5
|
15,066
|
14,365
|
5
|
5
|
|
- Alliance Revenue
|
2,806
|
2,108
|
33
|
32
|
1,107
|
815
|
36
|
36
|
|
Product
Revenue
|
46,768
|
43,143
|
8
|
6
|
16,173
|
15,180
|
7
|
7
|
|
Collaboration
Revenue
|
113
|
93
|
22
|
23
|
36
|
11
|
>3x
|
>3x
|
|
Total Revenue
|
46,881
|
43,236
|
8
|
7
|
16,209
|
15,191
|
7
|
7
|
|
Cost of
sales
|
(8,147)
|
(7,515)
|
8
|
3
|
(2,946)
|
(2,801)
|
5
|
2
|
|
Gross profit
|
38,734
|
35,721
|
8
|
7
|
13,263
|
12,390
|
7
|
8
|
|
Distribution
expense
|
(437)
|
(426)
|
3
|
(1)
|
(151)
|
(148)
|
3
|
2
|
|
R&D
expense
|
(11,439)
|
(10,370)
|
10
|
9
|
(3,894)
|
(3,663)
|
6
|
7
|
|
SG&A
expense
|
(15,679)
|
(14,441)
|
9
|
7
|
(5,108)
|
(5,085)
|
-
|
-
|
|
Other
operating income & expense
|
618
|
281
|
>2x
|
>2x
|
277
|
89
|
>3x
|
>3x
|
|
Operating profit
|
11,797
|
10,765
|
10
|
10
|
4,387
|
3,583
|
22
|
26
|
|
Net
finance expense
|
(1,085)
|
(985)
|
10
|
9
|
(410)
|
(349)
|
17
|
22
|
|
Joint
ventures and associates
|
(41)
|
(7)
|
>5x
|
>5x
|
(19)
|
10
|
n/m
|
n/m
|
|
Profit before tax
|
10,671
|
9,773
|
9
|
10
|
3,958
|
3,244
|
22
|
25
|
|
Taxation
|
(1,966)
|
(1,869)
|
5
|
6
|
(842)
|
(709)
|
19
|
22
|
|
Tax rate
|
18%
|
19%
|
|
|
21%
|
22%
|
|
|
|
Profit after tax
|
8,705
|
7,904
|
10
|
11
|
3,116
|
2,535
|
23
|
26
|
|
Earnings per share
|
$5.62
|
$5.10
|
10
|
11
|
$2.02
|
$1.64
|
23
|
26
|
Table
9: Reconciliation of Reported Profit before tax to
EBITDA
|
|
9M 2026
|
9M 2025
|
%
Change
|
Q3 2026
|
Q3 2025
|
%
Change
|
||
|
|
$m
|
$m
|
Actual
|
CER
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit before tax
|
10,671
|
9,773
|
9
|
10
|
3,958
|
3,244
|
22
|
25
|
|
Net
finance expense
|
1,085
|
985
|
10
|
9
|
410
|
349
|
17
|
22
|
|
Joint
ventures and associates
|
41
|
7
|
>5x
|
>5x
|
19
|
(10)
|
n/m
|
n/m
|
|
Depreciation,
amortisation and impairment
|
4,900
|
4,222
|
16
|
15
|
1,605
|
1,549
|
4
|
4
|
|
EBITDA
|
16,697
|
14,987
|
11
|
11
|
5,992
|
5,132
|
17
|
19
|
Table
10: Reconciliation of Reported to Core financial measures: 9M
2026
|
For the nine
months ended 30
September
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Other
|
Core
|
% Change
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross profit
|
38,734
|
13
|
19
|
3
|
38,769
|
9
|
7
|
|
- Gross Margin
|
83%
|
|
|
|
83%
|
-
|
+1pp
|
|
Distribution
expense
|
(437)
|
1
|
-
|
-
|
(436)
|
2
|
(1)
|
|
R&D
expense
|
(11,439)
|
157
|
511
|
3
|
(10,768)
|
7
|
5
|
|
- R&D % of Total Revenue
|
24%
|
|
|
|
23%
|
-
|
-
|
|
SG&A
expense
|
(15,679)
|
258
|
3,194
|
409
|
(11,818)
|
7
|
4
|
|
- SG&A % of Total Revenue
|
33%
|
|
|
|
25%
|
-
|
+1pp
|
|
Total
operating expense
|
(27,555)
|
416
|
3,705
|
412
|
(23,022)
|
7
|
5
|
|
Other
operating income & expense
|
618
|
(1)
|
-
|
1
|
618
|
>2x
|
>2x
|
|
Operating profit
|
11,797
|
428
|
3,724
|
416
|
16,365
|
14
|
14
|
|
- Operating Margin
|
25%
|
|
|
|
35%
|
+2pp
|
+2pp
|
|
Net
finance expense
|
(1,085)
|
-
|
-
|
93
|
(992)
|
21
|
20
|
|
Taxation
|
(1,966)
|
(103)
|
(738)
|
(122)
|
(2,929)
|
11
|
12
|
|
EPS
|
$5.62
|
$0.21
|
$1.93
|
$0.24
|
$8.00
|
14
|
14
|
Table
11: Reconciliation of Reported to Core financial measures: Q3
2026
|
For the quarter ended 30 September
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Other
|
Core
|
% Change
|
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross profit
|
13,263
|
16
|
3
|
-
|
13,282
|
7
|
8
|
|
- Gross Margin
|
82%
|
|
|
|
82%
|
-
|
+1pp
|
|
Distribution
expense
|
(151)
|
1
|
-
|
-
|
(150)
|
2
|
1
|
|
R&D
expense
|
(3,894)
|
100
|
147
|
2
|
(3,645)
|
3
|
3
|
|
- R&D % of Total Revenue
|
24%
|
|
|
|
22%
|
+1pp
|
+1pp
|
|
SG&A
expense
|
(5,108)
|
152
|
1,038
|
9
|
(3,909)
|
2
|
2
|
|
- SG&A % of Total Revenue
|
32%
|
|
|
|
24%
|
+1pp
|
+1pp
|
|
Total
operating expense
|
(9,153)
|
253
|
1,185
|
11
|
(7,704)
|
2
|
2
|
|
Other
operating income & expense
|
277
|
(1)
|
-
|
1
|
277
|
>2x
|
>2x
|
|
Operating profit
|
4,387
|
268
|
1,188
|
12
|
5,855
|
17
|
20
|
|
- Operating Margin
|
27%
|
|
|
|
36%
|
+3pp
|
+4pp
|
|
Net
finance expense
|
(410)
|
-
|
-
|
39
|
(371)
|
22
|
27
|
|
Taxation
|
(842)
|
(63)
|
(224)
|
(11)
|
(1,140)
|
14
|
16
|
|
EPS
|
$2.02
|
$0.13
|
$0.62
|
$0.02
|
$2.79
|
17
|
19
|
Profit and Loss drivers
Gross
profit
The
movement in Gross Margin (Reported and Core) in 9M 2026 was a
result of:
–
Positive effects
from geographic mix
–
The changing mix of
Product Sales with profit sharing arrangements (Lynparza, Enhertu, Datroway, Tezspire, plus Koselugo in the prior year period)
reduces Gross Margin because AstraZeneca records Product Sales in
certain markets and pays away a share of the gross profits to its
collaboration partners. The profit share paid to partners is
recorded in AstraZeneca’s Cost of sales line
–
Pricing adjustments
to medicines that have reached the end of their exclusivity
periods, and implementation of the US government agreement
announced in 2025
Variations
in Gross Margin performance between periods can continue to be
expected due to product seasonality, foreign exchange fluctuations,
and other effects.
R&D
expense
The
increase in R&D expense (Reported and Core) in the period was
driven by:
–
Positive data
readouts for high-value pipeline opportunities that have ungated
late-stage trials
–
Investment in
platforms, new technology and capabilities to enhance R&D
capabilities
–
Addition of R&D
projects following completion of previously announced business
development activity
–
The change in
Reported R&D expense also reflects impairment charges of $483m
recorded against intangible assets in 9M 2026
SG&A
expense
The
increase in SG&A expense (Reported and Core) in the period was
driven primarily by ongoing and future launches and to support
continued growth in existing brands.
Other
operating income and expense
The
increase in Other operating income and expense (Reported and Core)
was driven by increased royalty income and disposals of financial
interests in mature medicines such as Zoryve.
Net
finance expense
Core
Net finance expense increased 21% (20% at CER) in 9M 2026,
principally due to higher interest expense on short-term
borrowings, lower interest income on short-term deposits and higher
discount unwind on lease liabilities, also due to the prior year
benefitting from adjustments relating to settlements with tax
authorities.
Taxation
The
effective Reported and Core tax rates in 9M 2026 were 18% and 19%
respectively (9M 2025: both 19%). The cash tax paid in 9M 2026 was
$2,634m (9M 2025: $2,193m), representing 25% of Reported Profit
before tax (9M 2025: 22%).
Cash Flow
Table
12: Cash Flow summary: 9M 2026
|
For the nine
months ended 30
September
|
9M 2026
$m
|
9M 2025
$m
|
Change$m
|
|
Reported
Operating profit
|
11,797
|
10,765
|
1,032
|
|
Depreciation,
amortisation and impairment
|
4,900
|
4,222
|
678
|
|
Movement
in working capital and short-term provisions
|
(1,730)
|
64
|
(1,794)
|
|
Gains
on disposal of intangible assets
|
(156)
|
(118)
|
(38)
|
|
Fair
value movements on contingent consideration arising from business
combinations
|
(15)
|
(29)
|
14
|
|
Non-cash
and other movements
|
(125)
|
591
|
(716)
|
|
Interest
paid
|
(1,147)
|
(1,069)
|
(78)
|
|
Taxation
paid
|
(2,634)
|
(2,193)
|
(441)
|
|
Net cash inflow from operating activities
|
10,890
|
12,233
|
(1,343)
|
|
Net cash outflow from investing activities
|
(6,589)
|
(5,362)
|
(1,227)
|
|
Net cash outflow from financing activities
|
(2,066)
|
(4,262)
|
2,196
|
|
Net increase in cash and cash equivalents in the
period
|
2,235
|
2,609
|
(374)
|
Net
cash flow
The
decrease in Net cash inflow from operating activities of $1,343m
was primarily driven by Movement in working capital and short-term
provisions including the impact of Farxiga loss of exclusivity in the US,
higher taxation paid and foreign exchange fluctuations, offset by
increased Operating profit.
The
increase in Net cash outflow from investing activities of $1,227m
was primarily driven by increased Purchase of intangible assets,
including an upfront payment of $1,104m to CSPC Pharmaceuticals
during Q2 2026.
The decrease in Net cash outflow from
financing activities of $2,196m was primarily driven by the issue
of new long-term loans of $4,972m, partially offset by the
repayment of long-term loans of $2,456m in 9M 2026. There were no
significant issuances or repayments of long-term loans in 9M
2025.
Capital
expenditure
Capital
expenditure on Property, plant and equipment and software-related
intangible assets amounted to $2,284m in 9M 2026 (9M 2025:
$2,091m). The increase of capital expenditure in 9M 2026 was driven
by investment in several major manufacturing projects and continued
investment in technology upgrades.
Net
debt
Net
debt increased by $2,459m in the nine months to 30 September 2026
to $25,833m. Details of the committed undrawn bank facilities are
disclosed within the Going concern section of Note 1. Details of
the Company's solicited credit ratings and further details on Net
debt are disclosed in Note 3.
Net debt
Table
13: Net debt summary
|
|
At 30 Sep 2026
$m
|
At 31 Dec 2025
$m
|
At 30 Sep 2025
$m
|
|
Cash
and cash equivalents
|
7,936
|
5,711
|
8,143
|
|
Other
investments
|
230
|
30
|
39
|
|
Cash and investments
|
8,166
|
5,741
|
8,182
|
|
Overdrafts
and short-term borrowings
|
(473)
|
(644)
|
(622)
|
|
Commercial
paper
|
(1,619)
|
-
|
(1,091)
|
|
Lease
liabilities
|
(2,777)
|
(1,803)
|
(1,758)
|
|
Current
instalments of loans
|
(2,857)
|
(2,460)
|
(4,461)
|
|
Non-current
instalments of loans
|
(26,465)
|
(24,715)
|
(24,700)
|
|
Interest-bearing loans and borrowings (Gross debt)
|
(34,191)
|
(29,622)
|
(32,632)
|
|
Net
derivatives
|
192
|
507
|
485
|
|
Net debt
|
(25,833)
|
(23,374)
|
(23,965)
|
Summarised
financial information for guarantee of securities of
subsidiaries
AstraZeneca
Finance LLC ("AstraZeneca Finance") is the issuer of 4.800% Notes
due 2027, 4.875% Notes due 2028, 1.750% Notes due 2028, 4.850%
Notes due 2029, 4.900% Notes due 2030, 4.900% Notes due 2031,
2.250% Notes due 2031, 4.000% Notes due 2031, 4.875% Notes due
2033, 4.300% Notes due 2033, 5.000% Notes due 2034 and 4.600% Notes
due 2036 (the "AstraZeneca Finance USD Notes"). Each series of
AstraZeneca Finance USD Notes has been fully and unconditionally
guaranteed by AstraZeneca PLC. AstraZeneca Finance is 100% owned by
AstraZeneca PLC and each of the guarantees issued by AstraZeneca
PLC is full and unconditional and joint and several.
The
AstraZeneca Finance USD Notes are senior unsecured obligations of
AstraZeneca Finance and rank equally with all of AstraZeneca
Finance's existing and future senior unsecured and unsubordinated
indebtedness. The guarantee by AstraZeneca PLC of the AstraZeneca
Finance USD Notes is the senior unsecured obligation of AstraZeneca
PLC and ranks equally with all of AstraZeneca PLC's existing and
future senior unsecured and unsubordinated indebtedness. Each
guarantee by AstraZeneca PLC is effectively subordinated to any
secured
indebtedness
of AstraZeneca PLC to the extent of the value of the assets
securing such indebtedness. The AstraZeneca Finance USD Notes are
structurally subordinated to indebtedness and other liabilities of
the subsidiaries of AstraZeneca PLC, none of which guarantee the
AstraZeneca Finance USD Notes.
AstraZeneca
PLC manages substantially all of its operations through divisions,
branches and/or investments in subsidiaries and affiliates.
Accordingly, the ability of AstraZeneca PLC to service its debt and
guarantee obligations is also dependent upon the earnings of its
subsidiaries, affiliates, branches and divisions, whether by
dividends, distributions, loans or otherwise. Please refer to the
Consolidated financial statements of AstraZeneca PLC in our Annual
Report on Form 20-F as filed with the SEC and information contained
herein for further financial information regarding AstraZeneca PLC
and its consolidated subsidiaries. For further details, terms and
conditions of the AstraZeneca Finance USD Notes please refer to
AstraZeneca PLC's reports on Form 6-K furnished to the SEC on 26
February 2026, 22 February 2024, 3 March 2023 and 28 May
2021.
Pursuant
to Rule 13-01 and Rule 3-10 of Regulation S-X under the Securities
Act of 1933, as amended (the "Securities Act"), we present below
the summary financial information for AstraZeneca PLC, as
Guarantor, excluding its consolidated subsidiaries, and AstraZeneca
Finance, as the issuer, excluding its consolidated subsidiaries.
The following summary financial information of AstraZeneca PLC and
AstraZeneca Finance is presented on a combined basis and
transactions between the combining entities have been eliminated.
Financial information for non-guarantor entities has been excluded.
Intercompany balances and transactions between the obligor group
and the non-obligor subsidiaries are presented on separate
lines.
Obligor group summarised statements
Table
14: Obligor group summarised Statement of comprehensive income: 9M
2026
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
Total
Revenue
|
-
|
-
|
|
Gross
profit
|
-
|
-
|
|
Operating
loss
|
(5)
|
-
|
|
Loss
for the period
|
(832)
|
(957)
|
|
Transactions
with subsidiaries that are not issuers or guarantors
|
6,740
|
6,509
|
Table
15: Obligor group summarised Statement of financial
position
|
|
At 30 Sep 2026
$m
|
At 30 Sep 2025
$m
|
|
Current
assets
|
129
|
13
|
|
Non-current
assets
|
11
|
141
|
|
Current
liabilities
|
(4,704)
|
(5,976)
|
|
Non-current
liabilities
|
(26,568)
|
(24,704)
|
|
Amounts
due from subsidiaries that are not issuers or
guarantors
|
25,450
|
21,519
|
|
Amounts
due to subsidiaries that are not issuers or guarantors
|
-
|
-
|
Capital allocation
The
Group’s capital allocation priorities include: investing in
the business and pipeline; maintaining a strong, investment-grade
credit rating; pursuing potential value-enhancing business
development opportunities; and supporting the progressive dividend
policy.
In
approving the declaration of dividends, the Board considers both
the liquidity of the Company and the level of reserves legally
available for distribution.
In FY
2026, the Company intends to increase the annual dividend declared
to $3.30 per share.
Dividends
are paid to shareholders from AstraZeneca PLC, a Group holding
company with no direct operations. The ability of AstraZeneca PLC
to make shareholder distributions is dependent on the creation of
profits for distribution and the receipt of funds from subsidiary
companies.
The
consolidated Group reserves set out in the Condensed consolidated
statement of financial position do not reflect the profit available
for distribution to the shareholders of AstraZeneca
PLC.
In FY
2025, capital expenditure on Property, plant and equipment and
Software-related intangible assets amounted to $3,270m. In FY 2026
the Group expects to increase expenditure on Property, plant and
equipment and Software-related intangible assets by a low-teens
percentage, driven by manufacturing expansion projects and
investments in systems and technology.
Foreign exchange
The
Company's transactional currency exposures on working capital
balances, which typically extend for up to three months, are hedged
where practicable using forward foreign exchange contracts against
the individual companies' reporting currency.
Foreign
exchange gains and losses on forward contracts transacted for
transactional hedging are taken to profit or to Other comprehensive
income if the contract is in a designated cash flow
hedge.
In
addition, the Company's external dividend payments paid in pound
sterling and Swedish krona, are fully hedged from the time of their
announcement to the payment date.
Table
16: Currency sensitivities
|
Currency
|
Primary Relevance
|
Exchange rate vs USD (average rate in period)
|
Annual impact of 5% strengthening vs USD1
($m)
|
|||||
|
|
|
FY 20252
|
YTD 20263
|
Change
(%)
|
Sep 20264
|
Change
(%)
|
Total Revenue
|
Core Operating Profit
|
|
EUR
|
Total
Revenue
|
0.88
|
0.86
|
3
|
0.87
|
2
|
499
|
234
|
|
CNY
|
Total
Revenue
|
7.19
|
6.82
|
5
|
6.71
|
7
|
329
|
178
|
|
JPY
|
Total
Revenue
|
149.64
|
158.51
|
(6)
|
156.40
|
(5)
|
179
|
120
|
|
GBP
|
Operating
expense
|
0.76
|
0.74
|
2
|
0.75
|
2
|
50
|
(180)
|
|
SEK
|
Operating
expense
|
9.81
|
9.38
|
4
|
9.75
|
1
|
9
|
(71)
|
|
Other
|
|
|
|
|
|
|
615
|
339
|
1. Assumes the average exchange rate vs USD in FY
2026 is 5% higher than the average rate in FY 2025. The impact data
are estimates, based on best prevailing assumptions around currency
profiles.
2. Based on average daily spot rates 1 January 2025
to 31 December 2025.
3. Based on average daily spot rates 1 January 2026
to 30 September 2026.
4. Based on average daily spot rates 1 September 2026
to 30 September 2026.
Interim
financial statements
Table
17: Condensed consolidated statement of comprehensive income: 9M
2026
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
- Product Sales
|
43,962
|
41,035
|
|
- Alliance Revenue
|
2,806
|
2,108
|
|
Product
Revenue
|
46,768
|
43,143
|
|
Collaboration
Revenue
|
113
|
93
|
|
Total Revenue
|
46,881
|
43,236
|
|
Cost of
sales
|
(8,147)
|
(7,515)
|
|
Gross profit
|
38,734
|
35,721
|
|
Distribution
expense
|
(437)
|
(426)
|
|
Research
and development expense
|
(11,439)
|
(10,370)
|
|
Selling,
general and administrative expense
|
(15,679)
|
(14,441)
|
|
Other
operating income and expense
|
618
|
281
|
|
Operating profit
|
11,797
|
10,765
|
|
Finance
income
|
217
|
225
|
|
Finance
expense
|
(1,302)
|
(1,210)
|
|
Share
of after tax losses in associates and joint ventures
|
(41)
|
(7)
|
|
Profit before tax
|
10,671
|
9,773
|
|
Taxation
|
(1,966)
|
(1,869)
|
|
Profit for the period
|
8,705
|
7,904
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
Items that will not be reclassified to profit and
loss:
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
268
|
116
|
|
Net
gains/(losses) on equity investments measured at fair value through
Other comprehensive income
|
529
|
(21)
|
|
Tax
expense on items that will not be reclassified to profit or
loss
|
(77)
|
(13)
|
|
|
720
|
82
|
|
Items that may be reclassified subsequently to profit and
loss:
|
|
|
|
Foreign
exchange arising on consolidation
|
(862)
|
2,266
|
|
Foreign
exchange arising on designated liabilities in net investment
hedges
|
47
|
15
|
|
Fair
value movements on cash flow hedges
|
(12)
|
256
|
|
Fair
value movements on cash flow hedges transferred to profit and
loss
|
114
|
(318)
|
|
Fair
value movements on derivatives designated in net investment
hedges
|
(17)
|
(7)
|
|
(Costs)/gains
of hedging
|
(70)
|
8
|
|
Tax
expense on items that may be reclassified subsequently to profit
and loss
|
(14)
|
(50)
|
|
|
(814)
|
2,170
|
|
Other comprehensive (expense)/income for the period, net of
tax
|
(94)
|
2,252
|
|
|
|
|
|
Total comprehensive income for the period
|
8,611
|
10,156
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
Owners
of the Parent
|
8,704
|
7,899
|
|
Non-controlling
interests
|
1
|
5
|
|
|
8,705
|
7,904
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
Owners
of the Parent
|
8,612
|
10,149
|
|
Non-controlling
interests
|
(1)
|
7
|
|
|
8,611
|
10,156
|
|
Earnings per share
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
$5.62
|
$5.10
|
|
Diluted
earnings per $0.25 Ordinary Share
|
$5.58
|
$5.06
|
|
Weighted
average number of Ordinary Shares in issue (millions)
|
1,550
|
1,550
|
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
1,561
|
1,561
|
Table
18: Condensed consolidated statement of comprehensive income: Q3
2026
|
For the quarter ended 30 September
|
2026
$m
|
2025
$m
|
|
- Product Sales
|
15,066
|
14,365
|
|
- Alliance Revenue
|
1,107
|
815
|
|
Product
Revenue
|
16,173
|
15,180
|
|
Collaboration
Revenue
|
36
|
11
|
|
Total Revenue
|
16,209
|
15,191
|
|
Cost of
sales
|
(2,946)
|
(2,801)
|
|
Gross profit
|
13,263
|
12,390
|
|
Distribution
expense
|
(151)
|
(148)
|
|
Research
and development expense
|
(3,894)
|
(3,663)
|
|
Selling,
general and administrative expense
|
(5,108)
|
(5,085)
|
|
Other
operating income and expense
|
277
|
89
|
|
Operating profit
|
4,387
|
3,583
|
|
Finance
income
|
67
|
85
|
|
Finance
expense
|
(477)
|
(434)
|
|
Share
of after tax (losses)/gains in associates and joint
ventures
|
(19)
|
10
|
|
Profit before tax
|
3,958
|
3,244
|
|
Taxation
|
(842)
|
(709)
|
|
Profit for the period
|
3,116
|
2,535
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
Items that will not be reclassified to profit and
loss:
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
35
|
146
|
|
Net
gains on equity investments measured at fair value through Other
comprehensive income
|
64
|
104
|
|
Tax
expense on items that will not be reclassified to profit or
loss
|
(26)
|
(10)
|
|
|
73
|
240
|
|
Items that may be reclassified subsequently to profit and
loss:
|
|
|
|
Foreign
exchange arising on consolidation
|
(163)
|
(198)
|
|
Foreign
exchange arising on designated liabilities in net investment
hedges
|
4
|
5
|
|
Fair
value movements on cash flow hedges
|
69
|
(17)
|
|
Fair
value movements on cash flow hedges transferred to profit and
loss
|
18
|
(3)
|
|
Fair
value movements on derivatives designated in net investment
hedges
|
(21)
|
13
|
|
Costs
of hedging
|
(70)
|
(2)
|
|
Tax
(expense)/income on items that may be reclassified subsequently to
profit and loss
|
(21)
|
2
|
|
|
(184)
|
(200)
|
|
Other comprehensive (expense)/income for the period, net of
tax
|
(111)
|
40
|
|
|
|
|
|
Total comprehensive income for the period
|
3,005
|
2,575
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
Owners
of the Parent
|
3,117
|
2,533
|
|
Non-controlling
interests
|
(1)
|
2
|
|
|
3,116
|
2,535
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
Owners
of the Parent
|
3,006
|
2,575
|
|
Non-controlling
interests
|
(1)
|
-
|
|
|
3,005
|
2,575
|
|
Earnings per share
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
$2.02
|
$1.64
|
|
Diluted
earnings per $0.25 Ordinary Share
|
$2.00
|
$1.62
|
|
Weighted
average number of Ordinary Shares in issue (millions)
|
1,551
|
1,551
|
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
1,560
|
1,561
|
Table
19: Condensed consolidated statement of financial
position
|
|
|
At 30
Sep 2026
|
At 31
Dec 2025
|
At 30
Sep 2025
|
|
Assets
|
|
$m
|
$m
|
$m
|
|
Non-current assets
|
|
|
|
|
|
Property,
plant and equipment
|
|
14,064
|
12,962
|
12,083
|
|
Right-of-use
assets
|
|
2,714
|
1,741
|
1,700
|
|
Goodwill
|
|
21,157
|
21,242
|
21,219
|
|
Intangible
assets
|
|
38,146
|
37,846
|
38,191
|
|
Investments
in associates and joint ventures
|
|
268
|
302
|
296
|
|
Other
investments
|
|
2,676
|
2,223
|
1,990
|
|
Derivative
financial instruments
|
|
306
|
498
|
502
|
|
Other
receivables
|
|
1,426
|
1,327
|
1,159
|
|
Income
tax receivable
|
|
1,062
|
1,391
|
1,247
|
|
Deferred
tax assets
|
|
6,655
|
5,819
|
6,129
|
|
|
|
88,474
|
85,351
|
84,516
|
|
Current assets
|
|
|
|
|
|
Inventories
|
|
6,883
|
6,557
|
6,593
|
|
Trade
and other receivables
|
|
14,736
|
15,177
|
14,338
|
|
Other
investments
|
|
230
|
30
|
39
|
|
Derivative
financial instruments
|
|
20
|
90
|
12
|
|
Income
tax receivable
|
|
1,643
|
1,158
|
815
|
|
Cash
and cash equivalents
|
|
7,936
|
5,711
|
8,143
|
|
|
|
31,448
|
28,723
|
29,940
|
|
Total assets
|
|
119,922
|
114,074
|
114,456
|
|
Liabilities
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(4,949)
|
(3,104)
|
(6,174)
|
|
Lease
liabilities
|
|
(445)
|
(382)
|
(379)
|
|
Trade
and other payables
|
|
(23,572)
|
(25,280)
|
(25,028)
|
|
Derivative
financial instruments
|
|
(26)
|
(81)
|
(29)
|
|
Provisions
|
|
(654)
|
(686)
|
(1,176)
|
|
Income
tax payable
|
|
(1,621)
|
(1,084)
|
(1,268)
|
|
|
|
(31,267)
|
(30,617)
|
(34,054)
|
|
Non-current liabilities
|
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(26,465)
|
(24,715)
|
(24,700)
|
|
Lease
liabilities
|
|
(2,332)
|
(1,421)
|
(1,379)
|
|
Derivative
financial instruments
|
|
(108)
|
-
|
-
|
|
Deferred
tax liabilities
|
|
(3,617)
|
(3,500)
|
(3,604)
|
|
Retirement
benefit obligations
|
|
(780)
|
(1,105)
|
(1,271)
|
|
Provisions
|
|
(988)
|
(918)
|
(929)
|
|
Income
tax payable
|
|
(293)
|
(700)
|
(535)
|
|
Other
payables
|
|
(2,258)
|
(2,379)
|
(2,013)
|
|
|
|
(36,841)
|
(34,738)
|
(34,431)
|
|
Total liabilities
|
|
(68,108)
|
(65,355)
|
(68,485)
|
|
Net assets
|
|
51,814
|
48,719
|
45,971
|
|
Equity
|
|
|
|
|
|
Share
capital
|
|
388
|
388
|
388
|
|
Share
premium account
|
|
35,286
|
35,266
|
35,243
|
|
Other
reserves
|
|
1,985
|
2,041
|
2,044
|
|
Retained
earnings
|
|
14,069
|
10,972
|
8,213
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
51,728
|
48,667
|
45,888
|
|
Non-controlling
interests
|
|
86
|
52
|
83
|
|
Total equity
|
|
51,814
|
48,719
|
45,971
|
Table
20: Condensed consolidated statement of changes in
equity
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the Parent
|
Non-controlling interests
|
Total equity
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January 2025
|
388
|
35,226
|
2,012
|
3,160
|
40,786
|
85
|
40,871
|
|
Profit
for the period
|
-
|
-
|
-
|
7,899
|
7,899
|
5
|
7,904
|
|
Other
comprehensive (expense)/income
|
-
|
-
|
(61)
|
2,311
|
2,250
|
2
|
2,252
|
|
Transfer
to Other reserves
|
-
|
-
|
48
|
(48)
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(4,846)
|
(4,846)
|
-
|
(4,846)
|
|
Dividends
paid to non-controlling interests
|
-
|
-
|
-
|
-
|
-
|
(2)
|
(2)
|
|
Issue
of Ordinary Shares
|
-
|
17
|
-
|
-
|
17
|
-
|
17
|
|
Changes
in non-controlling interests
|
-
|
-
|
-
|
8
|
8
|
(7)
|
1
|
|
Movement
in shares held by Employee Benefit Trusts
|
-
|
-
|
45
|
-
|
45
|
-
|
45
|
|
Share-based
payments charge for the period
|
-
|
-
|
-
|
529
|
529
|
-
|
529
|
|
Settlement
of share plan awards
|
-
|
-
|
-
|
(800)
|
(800)
|
-
|
(800)
|
|
Net movement
|
-
|
17
|
32
|
5,053
|
5,102
|
(2)
|
5,100
|
|
At 30 September 2025
|
388
|
35,243
|
2,044
|
8,213
|
45,888
|
83
|
45,971
|
|
|
|
|
|
|
|
|
|
|
At 1 January 2026
|
388
|
35,266
|
2,041
|
10,972
|
48,667
|
52
|
48,719
|
|
Profit
for the period
|
-
|
-
|
-
|
8,704
|
8,704
|
1
|
8,705
|
|
Other
comprehensive income/(expense)
|
-
|
-
|
27
|
(119)
|
(92)
|
(2)
|
(94)
|
|
Transfer
to Other reserves
|
-
|
-
|
10
|
(10)
|
-
|
-
|
-
|
|
Transactions with owners
|
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(5,002)
|
(5,002)
|
-
|
(5,002)
|
|
Dividends
paid to non-controlling interests
|
-
|
-
|
-
|
-
|
-
|
(2)
|
(2)
|
|
Issue
of Ordinary Shares
|
-
|
20
|
-
|
-
|
20
|
-
|
20
|
|
Changes
in non-controlling interests
|
-
|
-
|
-
|
-
|
-
|
37
|
37
|
|
Movement
in shares held by Employee Benefit Trusts
|
-
|
-
|
(93)
|
-
|
(93)
|
-
|
(93)
|
|
Share-based
payments charge for the period
|
-
|
-
|
-
|
574
|
574
|
-
|
574
|
|
Settlement
of share plan awards
|
-
|
-
|
-
|
(1,050)
|
(1,050)
|
-
|
(1,050)
|
|
Net movement
|
-
|
20
|
(56)
|
3,097
|
3,061
|
34
|
3,095
|
|
At 30 September 2026
|
388
|
35,286
|
1,985
|
14,069
|
51,728
|
86
|
51,814
|
Table
21: Condensed consolidated statement of cash flows: 9M
2026
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
Cash flows from operating activities
|
|
|
|
Profit
before tax
|
10,671
|
9,773
|
|
Finance
income and expense
|
1,085
|
985
|
|
Share
of after tax losses of associates and joint ventures
|
41
|
7
|
|
Depreciation,
amortisation and impairment
|
4,900
|
4,222
|
|
Movement
in working capital and short-term provisions
|
(1,730)
|
64
|
|
Gains
on disposal of intangible assets
|
(156)
|
(118)
|
|
Fair
value movements on contingent consideration arising from business
combinations
|
(15)
|
(29)
|
|
Non-cash
and other movements
|
(125)
|
591
|
|
Cash generated from operations
|
14,671
|
15,495
|
|
Interest
paid
|
(1,147)
|
(1,069)
|
|
Tax
paid
|
(2,634)
|
(2,193)
|
|
Net cash inflow from operating activities
|
10,890
|
12,233
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
Acquisition
of businesses, net of cash acquired1
|
(600)
|
(60)
|
|
Payment
of contingent consideration from business combinations
|
(290)
|
(897)
|
|
Purchase
of property, plant and equipment
|
(1,986)
|
(1,774)
|
|
Disposal
of property, plant and equipment
|
13
|
10
|
|
Purchase
of intangible assets
|
(3,862)
|
(2,844)
|
|
Disposal
of intangible assets
|
180
|
96
|
|
Purchase
of non-current asset investments
|
(18)
|
(218)
|
|
Disposal
of non-current asset investments
|
3
|
-
|
|
Movement
in short-term investments, fixed deposits and other investing
instruments
|
(196)
|
122
|
|
Payments
to associates and joint ventures
|
(14)
|
(10)
|
|
Interest
received
|
181
|
213
|
|
Net cash outflow from investing activities
|
(6,589)
|
(5,362)
|
|
Net cash inflow before financing activities
|
4,301
|
6,871
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
Proceeds
from issue of share capital
|
20
|
17
|
|
Own
shares purchased by Employee Benefit Trusts
|
(763)
|
(508)
|
|
Payments
to acquire non-controlling interests
|
-
|
(14)
|
|
Issue
of loans and borrowings
|
4,972
|
9
|
|
Repayment
of loans and borrowings
|
(2,456)
|
(20)
|
|
Dividends
paid
|
(4,955)
|
(4,968)
|
|
Hedge
contracts relating to dividend payments
|
(52)
|
113
|
|
Repayment
of obligations under leases
|
(282)
|
(273)
|
|
Movement
in short-term borrowings
|
1,450
|
1,382
|
|
Net cash outflow from financing activities
|
(2,066)
|
(4,262)
|
|
|
|
|
|
Net increase in Cash and cash equivalents in the
period
|
2,235
|
2,609
|
|
Cash
and cash equivalents at the beginning of the period
|
5,698
|
5,429
|
|
Exchange
rate effects
|
(16)
|
42
|
|
Cash and cash equivalents at the end of the period
|
7,917
|
8,080
|
|
|
|
|
|
Cash and cash equivalents consist of:
|
|
|
|
Cash
and cash equivalents
|
7,936
|
8,143
|
|
Overdrafts
|
(19)
|
(63)
|
|
|
7,917
|
8,080
|
1. This item was previously named “Acquisition
of subsidiaries, net of cash acquired”.
Notes
to the Interim financial statements
Note
1: Basis of preparation and accounting policies
These unaudited Interim financial statements for 9M and Q3 ended 30
September 2026 have been prepared in accordance with International
Accounting Standard 34, ‘Interim Financial Reporting’
(IAS 34), as issued by the International Accounting Standards Board
(IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34
and the Disclosure Guidance and Transparency Rules sourcebook of
the United Kingdom’s Financial Conduct Authority and with the
requirements of the Companies Act 2006 as applicable to companies
reporting under those standards.
The unaudited Interim financial statements for 9M and Q3 ended 30
September 2026 were approved by the Board of Directors for
publication on 30 October 2026.
This results announcement does not constitute statutory accounts of
the Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The annual financial statements of the Group
for the year ended 31 December 2025 were prepared in accordance
with UK-adopted international accounting standards and with the
requirements of the Companies Act 2006. The annual financial
statements also comply fully with IFRS Accounting Standards as
issued by the IASB and International Accounting Standards as
adopted by the European Union. Except for the estimation of the
interim income tax charge, the Interim financial statements have
been prepared applying the accounting policies that were applied in
the preparation of the Group’s published consolidated
financial statements for the year ended 31 December
2025.
The
comparative figures for the financial year ended 31 December 2025
are not the Group’s statutory accounts for that financial
year. Those accounts have been reported on by the Group’s
auditors and have been delivered to the Registrar of Companies;
their report (i) was unqualified, (ii) did not include a reference
to any matters to which the auditors drew attention by way of
emphasis without qualifying their report, and (iii) did not contain
a statement under section 498(2) or (3) of the Companies Act
2006.
Going
concern
The
Group has considerable financial resources available. As at 30
September 2026, the Group has $12.8bn in financial resources (Cash
and cash equivalents of $7.9bn and undrawn committed bank
facilities of $4.9bn that are available until April 2031), with
$5.4bn of borrowings due within one year. These facilities contain
no financial covenants.
The
Group has assessed the prospects of the Group over a period of at
least 12 months from the date of Board approval of these
consolidated financial statements, with no deterioration noted
requiring a further extension of this review. The Group's revenues
are largely derived from sales of medicines covered by patents,
which provide a relatively high level of resilience and
predictability to cash inflows, although government price
interventions in response to budgetary constraints are expected to
continue to adversely affect revenues in some of our significant
markets. The Group, however, anticipates new revenue streams from
both recently launched medicines and those in development, and the
Group has a wide diversity of customers and suppliers across
different geographic areas.
Consequently,
the Directors believe that, overall, the Group is well placed to
manage its business risks successfully. Accordingly, they continue
to adopt the going concern basis in preparing the Interim financial
statements.
Legal
proceedings
The
information contained in Note 6 updates the disclosures concerning
legal proceedings and contingent liabilities in the Group's
Annual Report and Form 20-F
Information 2025.
Note 2: Intangible assets
An
intangible asset of $946m has been recognised in Q3 2026 comprising
the rights to Zegfrovy from
Dizal Pharmaceutical Co., Ltd (see Note 5).
During
Q3, impairment charges recorded against products in development
totalled $138m recorded within R&D expense.
During
Q2, as previously announced, the strategic collaboration and
license agreement with CSPC Pharmaceuticals closed. Under this
agreement, the companies will initially progress four programmes,
which utilise CSPC Pharmaceuticals’ advanced AI-driven
peptide drug discovery platform and their proprietary LiquidGel
once-monthly dosing platform technology. AstraZeneca paid an
upfront payment of $1.2bn, of which $1.1bn was capitalised within
intangible assets in Q2 2026. Contingent consideration of up to
$3.5bn could be paid on achievement of regulatory milestones; these
potential liabilities would be recorded when the relevant
recognition event for a regulatory milestone is achieved. Further
contingent sales milestones, as well as tiered royalties, could be
payable and would be recognised when the associated milestones are
triggered.
Note 3: Net debt
Table
22: Net debt
|
|
At 1 Jan 2026
|
Cash flow
|
Non-cash
and other
|
Exchange
movements
|
At 30 Sep 2026
|
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current
instalments of loans
|
(24,715)
|
(4,952)
|
2,979
|
223
|
(26,465)
|
|
Non-current
instalments of leases
|
(1,421)
|
-
|
(930)
|
19
|
(2,332)
|
|
Total long-term debt
|
(26,136)
|
(4,952)
|
2,049
|
242
|
(28,797)
|
|
Current
instalments of loans
|
(2,460)
|
2,453
|
(2,872)
|
22
|
(2,857)
|
|
Current
instalments of leases
|
(382)
|
368
|
(437)
|
6
|
(445)
|
|
Commercial
paper
|
-
|
(1,619)
|
-
|
-
|
(1,619)
|
|
Collateral
received from derivative counterparties
|
(473)
|
155
|
-
|
-
|
(318)
|
|
Other
short-term borrowings excluding overdrafts
|
(158)
|
14
|
-
|
8
|
(136)
|
|
Overdrafts
|
(13)
|
(6)
|
-
|
-
|
(19)
|
|
Total current debt
|
(3,486)
|
1,365
|
(3,309)
|
36
|
(5,394)
|
|
Gross borrowings
|
(29,622)
|
(3,587)
|
(1,260)
|
278
|
(34,191)
|
|
Net
derivative financial instruments
|
507
|
457
|
(772)
|
-
|
192
|
|
Net borrowings
|
(29,115)
|
(3,130)
|
(2,032)
|
278
|
(33,999)
|
|
Cash
and cash equivalents
|
5,711
|
2,241
|
-
|
(16)
|
7,936
|
|
Other
investments - current
|
30
|
200
|
-
|
-
|
230
|
|
Cash and investments
|
5,741
|
2,441
|
-
|
(16)
|
8,166
|
|
Net debt
|
(23,374)
|
(689)
|
(2,032)
|
262
|
(25,833)
|
The
table above provides an analysis of Net debt and a reconciliation
of Net cash flow to the movement in Net debt. The Group monitors
Net debt as part of its capital management policy as described in
Note 28 of the Annual Report and Form
20-F Information 2025. Net debt is a non-GAAP financial
measure.
Net
debt increased by $2,459m in the nine months to 30 September 2026
to $25,833m, which includes the issue of new long-term loans of
$4,972m, of which $20m was received from derivative financial
instruments designated as hedges of those loans, and the repayment
of long-term loans of $2,456m in 9M 2026. Details of the committed
undrawn bank facilities are disclosed within the going concern
section of Note 1. Non-cash movements in the period include
fair value adjustments under IFRS 9 'Financial
Instruments'.
The
Group has agreements with some bank counterparties whereby the
parties agree to post cash collateral on financial derivatives, for
the benefit of the other, equivalent to the market valuation of the
derivative positions above a predetermined threshold. The carrying
value of such cash collateral held by the Group at 30 September
2026 was $318m (31 December 2025: $473m) and the carrying value of
such cash collateral posted by the Group at 30 September 2026 was
$181m (31 December 2025: $22m).
The
equivalent GAAP measure to Net debt is 'liabilities arising from
financing activities', which excludes the amounts for cash and
overdrafts, other investments and non-financing derivatives
above.
During
the nine months ended 30 September 2026, there have been no changes
to the Group’s solicited credit ratings. Moody’s credit
ratings were long term: A1; short term: P-1. Standard and
Poor’s credit ratings were long term: A+; short term:
A-1.
Note 4: Financial Instruments
As
detailed in the Group's most recent annual financial statements,
the principal financial instruments consist of derivative financial
instruments, other investments, trade and other receivables, cash
and cash equivalents, trade and other payables, lease liabilities
and interest-bearing loans and borrowings.
The
Group has certain equity investments that are categorised as Level
3 in the fair value hierarchy that are held at $605m
(31 December 2025: $458m) and for which a fair value gain of
$158m has been recognised in the nine months ended 30 September
2026 (9M 2025: loss of $47m). In the absence of specific market
data, these unlisted investments are held at fair value based on
the cost of investment and adjusted as necessary for impairments
and revaluations on new funding rounds, which are seen to
approximate the fair value. All other fair value gains and/or
losses that are presented in Net gains/(losses) on equity
investments measured at fair value through Other comprehensive
income, in the Condensed consolidated statement of comprehensive
income for the nine months ended 30 September 2026, are
Level 1 fair value measurements, valued based on quoted prices
in active markets.
Financial
instruments measured at fair value include $2,724m of other
investments, $6,073m held in money-market funds and $192m of
derivatives as at 30 September 2026. With the exception of
derivatives being Level 2 fair valued, and certain equity
instruments of $605m categorised as Level 3, the aforementioned
balances are Level 1 fair valued. Financial instruments measured at
amortised cost include $181m of cash collateral pledged to
counterparties. The total fair value of Interest-bearing loans and
borrowings as at 30 September 2026, which have a carrying value of
$34,191m in the Condensed consolidated statement of financial
position, was $32,494m.
Contingent
consideration arising from business combinations is fair valued
using decision-tree analysis, with key inputs including the
probability of success, consideration of potential delays and the
expected levels of future revenues.
The
final contingent consideration payment of $257m relating to BMS's
share of the global diabetes alliance was made in Q1
2026.
Note 5: Business combinations
On 31
August 2026, AstraZeneca completed the exclusive license agreement
with Dizal Pharmaceutical Co., Ltd for Zegfrovy (sunvozertinib), an oral
irreversible epidermal growth factor receptor (EGFR) inhibitor for
patients with lung cancer. Through this acquisition agreement,
AstraZeneca has acquired worldwide rights to develop and
commercialise Zegfrovy,
along with China based employees and related contracts to support
the manufacture of Zegfrovy.
The
transaction is recorded as a business combination using the
acquisition method of accounting in accordance with IFRS 3
‘Business Combinations’. Consequently, the assets
acquired, and liabilities assumed are required to be recorded at
fair value. Given the proximity of the acquisition to the reporting
date, the purchase price allocation exercise under IFRS 3 is in
process, with the following items disclosed on a provisional
basis.
The
total consideration fair value of $946m includes upfront cash
consideration of $600m, and contingent consideration of $346m.
Additional future payments are contingent upon achievement of
specific development, regulatory and sales-related milestones.
Additionally, Dizal will receive tiered royalties on the global
sales of Zegfrovy. An
intangible asset of $946m has been recognised
comprising the
rights to Zegfrovy.
Note 6: Legal
proceedings and contingent liabilities
AstraZeneca
is involved in various legal proceedings considered typical to its
business, including litigation and investigations, including
Government investigations, relating to product liability,
commercial disputes, infringement of intellectual property (IP)
rights, the validity of certain patents, anti-trust law and sales
and marketing practices. The matters discussed below constitute the
more significant developments since publication of the disclosures
concerning legal proceedings in the Company's Annual Report and Form 20-F Information
2025 and the Interim Financial
Statements for the six months ended 30 June 2026 (the
Disclosures). Information about the nature and facts of the cases
is disclosed in accordance with IAS 37 ‘Provisions,
Contingent Liabilities and Contingent Assets’.
As
discussed in the Disclosures, the majority of claims involve highly
complex issues. Often these issues are subject to substantial
uncertainties and, therefore, the probability of a loss, if any,
being sustained and/or an estimate of the amount of any loss is
difficult to ascertain.
In
cases that have been settled or adjudicated, or where quantifiable
fines and penalties have been assessed and which are not subject to
appeal, or where a loss is probable and we are able to make a
reasonable estimate of the loss, AstraZeneca records the loss
absorbed or makes a provision for its best estimate of the expected
loss. The position could change over time and the estimates that
the Company made, and upon which the Company have relied in
calculating these provisions are inherently imprecise. There can,
therefore, be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed the amount of the
provisions that have been booked in the accounts. The major factors
causing this uncertainty are described more fully in the
Disclosures and herein.
AstraZeneca
has full confidence in, and will vigorously defend and enforce, its
IP.
Matters disclosed in respect of the third quarter of 2026 and up to
and including 29 October 2026
Patent
litigation
Legal
proceedings brought by AstraZeneca
|
Farxiga
patent proceedings,
US
|
*
In May
2021, AstraZeneca proceeded to trial against ANDA filer Zydus
Pharmaceuticals (USA) Inc. (Zydus) in the US District Court for the
District of Delaware (District Court). In October 2021, the
District Court issued a decision finding the asserted claims of
AstraZeneca’s patent as valid and infringed by Zydus’s
ANDA product. In August 2022, Zydus appealed the District Court
decision. Zydus’s appeal has been dismissed.
*
In
December 2023, AstraZeneca initiated ANDA litigation against Sun
Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries,
Inc. in the District Court. In September 2026, the District Court
dismissed the matter.
*
This
matter is concluded.
|
|
Koselugo
patent proceedings,
US
|
*
In
September 2026, AstraZeneca received a paragraph IV notice from
Hetero USA, Inc. challenging patents relating to Koselugo.
*
AstraZeneca intends
to file responsive ANDA litigation.
*
This
matter remains at an early stage.
|
|
Lynparza
patent proceedings,
Canada
|
* In
July 2025, AstraZeneca was served with a Notice of Allegation from
Cipla Ltd (Cipla) challenging a patent relating to Lynparza. AstraZeneca commenced an
action in response in August 2025. In August 2026, AstraZeneca
entered into a settlement agreement with Cipla resolving all Canada
patent litigation with Cipla relating to Lynparza.
*
In
August 2025, AstraZeneca was served with a Notice of Allegation
from Natco Pharma (Canada) Inc. (Natco) challenging a patent
relating to Lynparza.
AstraZeneca commenced an action in response in October 2025. In
September 2026, AstraZeneca entered into a settlement agreement
with Natco resolving all Canada patent litigation with Natco
relating to Lynparza.
* In
November 2025, AstraZeneca was served with a Notice of Allegation
from Zydus Lifesciences Limited challenging a patent relating to
Lynparza. AstraZeneca
commenced an action in response in December 2025. A summary trial
related to infringement is scheduled for January 2027 and a trial
on other matters has not yet been scheduled.
|
|
Lynparza
patent proceedings,
US
|
*
AstraZeneca
received a Paragraph IV notice relating to Lynparza patents from Natco Pharma
Limited (Natco) in December 2022, Sandoz Inc. (Sandoz) in December
2023, Cipla USA, Inc. and Cipla Limited (collectively, Cipla) in
May 2024, and Zydus Pharmaceuticals (USA) Inc. (Zydus) in November
2024.
*
In
response to these Paragraph IV notices, AstraZeneca, MSD
International Business GmbH, and the University of Sheffield
initiated ANDA litigations against Natco, Sandoz, Cipla, and Zydus
in the US District Court for the District of New Jersey. In the
complaints, AstraZeneca alleged that the defendants’ generic
versions of Lynparza, if
approved and marketed, would infringe AstraZeneca’s
patents.
*
In
April 2026, AstraZeneca entered into a settlement agreement with
Sandoz resolving all US patent litigation with Sandoz relating to
Lynparza.
*
Trial
has been scheduled to commence with the remaining defendants in
January 2027.
*
In June
2026, AstraZeneca received Paragraph IV notices from Cipla relating
to Lynparza dosage
strengths not at issue in the previous litigation. In July 2026,
AstraZeneca commenced responsive litigation. That matter remains at
an early stage.
|
|
Tagrisso
patent proceedings,
Russia
|
* In
August 2023, AstraZeneca filed lawsuits in the Arbitration Court of
the Moscow region (Court) against the Russian Ministry of Health
(MOH) and Axelpharm LLC (Axelpharm) for improper use of AstraZeneca
information in the authorisation of a generic version
of Tagrisso. The suit
against the MOH was dismissed in July 2024, after two appeals. The
case against Axelpharm was dismissed in September 2024, and a
subsequent appeal by AstraZeneca was also dismissed.
*
In
November 2023, Axelpharm sought a compulsory licence under a patent
related to Tagrisso;
the action remains pending. The Axelpharm patent on which the
compulsory licensing action was based was held invalid by the
Russian Patent and Trademark Office (PTO) in August 2024, following
a challenge by AstraZeneca. The PTO’s decision was upheld in
June 2025, following an appeal by Axelpharm. At a further appeal
hearing in November 2025, the Intellectual Property Court Presidium
reversed earlier decisions and held Axelpharm’s patent valid.
The Supreme Court rejected appeals by AstraZeneca and the PTO
against this decision in February 2026. AstraZeneca filed a
new invalidity claim against Axelpharm’s patent in May
2026.
*
In July
2024, AstraZeneca filed a patent infringement claim against
Axelpharm in relation to a generic version of Tagrisso. The action was stayed by the
Court pending resolution of the compulsory licensing action. In
July 2026, AstraZeneca filed a patent infringement claim against
OncoTarget LLC (OncoTarget) in relation to the manufacture of a
generic version of Tagrisso
and a further claim against Pharmproekt Limited Liability Company
based on their participation in tenders relating to a generic
version of Tagrisso.
*
In
August 2024, after AstraZeneca filed a complaint, the Federal
Anti-Monopoly Service of Russia (FAS) initiated a case against
Axelpharm and OncoTarget. In November 2024, the FAS found Axelpharm
(but not OncoTarget) to have committed unfair competition. In June
2025, the finding against Axelpharm was reversed on appeal. In
December 2025, on appeal by AstraZeneca, the appellate decision was
affirmed. AstraZeneca filed a further appeal, and in April 2026,
the Intellectual Property Court restored the FAS’s finding of
unfair competition and prohibited Axelpharm from selling the
generic drug.
|
Commercial
litigation
Legal
proceedings brought against AstraZeneca
|
Farxiga
Privacy Litigation,
US
Considered to be a contingent liability
|
*
In
September 2026, a putative class action was filed in California
State Court alleging that tracking technologies used on the
Farxiga website collected
and disclosed certain visitor information in violation of the
privacy laws of California and other states.
*
This
matter remains at an early stage.
|
|
Syntimmune Milestone Litigation, US
Considered to be a contingent liability
|
*
As
previously disclosed, since 2020, AstraZeneca has been defending a
lawsuit filed in connection with AstraZeneca's acquisition of
Syntimmune, Inc. (Syntimmune) by the stockholders’
representative for Syntimmune in Delaware State Court (Court) that
alleged, among other things, breaches of the 2018 merger agreement
(Merger Agreement).
*
The
stockholders’ representative alleged that AstraZeneca failed
to meet its obligations under the Merger Agreement to use
commercially reasonable efforts to achieve the milestones.
AstraZeneca also filed a claim for breach of the representations in
the Merger Agreement.
*
A trial
was held in July 2023. The Court issued partial decisions in
September 2024, June 2025, and May 2026, concluding that the first
milestone was achieved, that AstraZeneca had breached its
contractual obligation to use commercially reasonable efforts to
achieve the milestones, and that sellers breached a material
representation in the Merger Agreement regarding manufacturing of
drug substance and product supply.
*
In October 2026,
the Court entered final judgment on its earlier decisions issuing a
$392 million judgment, plus post judgment interest, against
AstraZeneca.
*
AstraZeneca intends
to appeal.
|
Government
investigations and proceedings
Legal
proceedings brought against AstraZeneca
|
Respiratory Biologics False Claims
Act Litigation, US
Considered to be a contingent liability
|
*
In
October 2026, AstraZeneca was served with an unsealed civil lawsuit
brought by qui tam relators on behalf of the federal government and
several states, which alleges that AstraZeneca engaged in unlawful
marketing practices in connection with its promotion of
Fasenra and Tezspire. Several other manufacturers
are also named in the complaint with respect to their promotion of
other respiratory biologics.
*
This
matter remains at an early stage.
|
Legal
proceedings brought by AstraZeneca
|
340B State Litigation, US
Considered to be a contingent asset
|
*
AstraZeneca has
ongoing lawsuits against Arkansas, Colorado, Hawaii, Louisiana,
Maine, Maryland, Mississippi, Missouri, Nebraska, New Mexico, North
Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee,
Utah, Vermont, Washington, and West Virginia challenging the
constitutionality of each state’s 340B statute.
*
AstraZeneca has
ongoing enforcement actions in Arkansas and Louisiana for alleged
non-compliance with each state's 340B statute. In July 2026,
Louisiana issued a cease-and-desist letter concerning AstraZeneca's
340B policy.
*
In
August and September 2026, the Mississippi and Arkansas District
Courts, respectively, granted summary judgment in favor of those
states. AstraZeneca has appealed or intends to appeal those
decisions.
*
In
August 2026, courts in Colorado, Maine, and South Dakota dismissed
AstraZeneca’s complaints. AstraZeneca has
appealed.
* In
August
2026, AstraZeneca was served with an unfair trade practices
complaint by the State of Arkansas concerning its 340B
policies.
|
|
Calquence
Inflation Reduction Act Litigation,
US
Considered to be a contingent asset
|
*
In
December 2025, AstraZeneca filed a lawsuit in the US District Court
for the District of Maryland (District Court) challenging the
Center for Medicare and Medicaid Studies' interpretation of
“qualifying single source drug” under the Inflation
Reduction Act and its application in selecting Calquence for drug price
negotiation.
*
In
August 2026, the District Court entered judgment against
AstraZeneca and AstraZeneca appealed.
|
|
Tagrisso
Regulatory Proceedings, UK and
Europe
|
*
In May
2026, AstraZeneca filed separate legal actions in the UK High Court
and the General Court of the European Union challenging
determinations by the Medicines and Healthcare products Regulatory
Agency and the *
European Medicines
Agency to grant marketing authorizations for Hansoh’s
aumolertinib. No trial date has been set.
*
In
September 2026, the European Commission revoked the marketing
authorization for aumolertinib.
|
Other
Additional
government inquiries
As is
true for most, if not all, major prescription pharmaceutical
companies, AstraZeneca is currently involved in multiple inquiries
into drug marketing and pricing practices. In addition to the
investigations described above, various law enforcement offices
have, from time to time, requested information from the Group.
There have been no material developments in those
matters.
Note 7: Subsequent events
On 5
October 2026, AstraZeneca completed its $2.0 billion equity
investment in Summit Therapeutics Inc., with the full amount paid
at closing. The investment gives AstraZeneca rights equivalent to
approximately 12.0% of Summit Therapeutics outstanding common
stock, or approximately 10.6% on a fully diluted basis, and has
been recognised as a non-current investment in Q4
2026.
Note 8: Analysis of Revenue and Other operating income and
expense
Table
23: Product Sales year-on-year analysis: 9M 2026
|
For the nine
months
|
World
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|||||||||
|
ended 30 September
|
|
Change
|
|
Change
|
|
Change
|
|
Change
|
|
Change
|
||||
|
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
CER %
|
|
Tagrisso
|
5,862
|
10
|
8
|
2,467
|
11
|
1,656
|
10
|
6
|
1,169
|
13
|
8
|
570
|
(3)
|
1
|
|
Imfinzi
|
5,538
|
28
|
27
|
3,128
|
26
|
627
|
35
|
33
|
1,210
|
38
|
31
|
573
|
17
|
23
|
|
Calquence
|
3,009
|
18
|
16
|
1,982
|
16
|
214
|
31
|
25
|
690
|
21
|
16
|
123
|
6
|
6
|
|
Lynparza
|
2,421
|
1
|
(2)
|
1,012
|
(4)
|
507
|
4
|
(1)
|
710
|
6
|
1
|
192
|
-
|
3
|
|
Enhertu
|
1,019
|
49
|
45
|
-
|
-
|
701
|
47
|
44
|
205
|
41
|
33
|
113
|
78
|
75
|
|
Zoladex
|
932
|
9
|
5
|
18
|
35
|
745
|
13
|
8
|
119
|
6
|
1
|
50
|
(24)
|
(26)
|
|
Truqap
|
641
|
30
|
29
|
450
|
9
|
55
|
n/m
|
n/m
|
97
|
n/m
|
n/m
|
39
|
82
|
87
|
|
Imjudo
|
263
|
4
|
4
|
157
|
(5)
|
33
|
89
|
86
|
43
|
21
|
16
|
30
|
(14)
|
(10)
|
|
Datroway
|
12
|
n/m
|
n/m
|
-
|
-
|
11
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Etcamah
|
10
|
n/m
|
n/m
|
7
|
n/m
|
3
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
Oncology
|
311
|
(3)
|
(4)
|
7
|
20
|
215
|
-
|
(3)
|
12
|
(20)
|
(21)
|
77
|
(11)
|
(5)
|
|
Oncology
|
20,018
|
16
|
14
|
9,228
|
14
|
4,767
|
19
|
15
|
4,256
|
22
|
16
|
1,767
|
6
|
10
|
|
Farxiga
|
5,602
|
(12)
|
(15)
|
795
|
(36)
|
2,200
|
(16)
|
(21)
|
2,385
|
11
|
6
|
222
|
(32)
|
(30)
|
|
Crestor
|
1,017
|
8
|
5
|
27
|
(25)
|
912
|
13
|
9
|
1
|
28
|
(14)
|
77
|
(19)
|
(16)
|
|
Lokelma
|
638
|
23
|
23
|
239
|
6
|
149
|
50
|
44
|
136
|
50
|
44
|
114
|
13
|
20
|
|
Seloken
|
518
|
11
|
6
|
-
|
n/m
|
500
|
11
|
6
|
15
|
6
|
3
|
3
|
6
|
(4)
|
|
Brilinta
|
261
|
(61)
|
(62)
|
16
|
(95)
|
207
|
2
|
(1)
|
33
|
(75)
|
(76)
|
5
|
(33)
|
(36)
|
|
Wainua
|
189
|
33
|
33
|
170
|
24
|
5
|
39
|
47
|
12
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
|
roxadustat
|
78
|
(66)
|
(67)
|
-
|
-
|
78
|
(66)
|
(67)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Baxfendy
|
12
|
n/m
|
n/m
|
11
|
n/m
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
CVRM
|
298
|
(29)
|
(30)
|
(11)
|
n/m
|
212
|
2
|
-
|
55
|
(54)
|
(55)
|
42
|
(11)
|
(6)
|
|
CVRM
|
8,613
|
(11)
|
(15)
|
1,247
|
(38)
|
4,264
|
(8)
|
(12)
|
2,637
|
5
|
-
|
465
|
(20)
|
(17)
|
|
Symbicort
|
2,084
|
(4)
|
(7)
|
772
|
(15)
|
653
|
5
|
1
|
425
|
5
|
(1)
|
234
|
(5)
|
(7)
|
|
Fasenra
|
1,655
|
14
|
13
|
949
|
7
|
149
|
85
|
78
|
389
|
11
|
5
|
168
|
26
|
30
|
|
Breztri
|
1,073
|
18
|
16
|
479
|
4
|
329
|
38
|
31
|
183
|
34
|
28
|
82
|
19
|
21
|
|
Tezspire
|
509
|
61
|
57
|
-
|
-
|
64
|
n/m
|
n/m
|
322
|
56
|
49
|
123
|
43
|
48
|
|
Saphnelo
|
615
|
27
|
27
|
516
|
23
|
18
|
72
|
72
|
57
|
68
|
61
|
24
|
36
|
41
|
|
Pulmicort
|
378
|
6
|
2
|
5
|
43
|
309
|
10
|
6
|
42
|
(9)
|
(14)
|
22
|
(19)
|
(19)
|
|
Airsupra
|
129
|
12
|
13
|
120
|
6
|
9
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
R&I
|
182
|
(14)
|
(16)
|
22
|
(67)
|
79
|
(17)
|
(20)
|
76
|
74
|
68
|
5
|
(6)
|
(6)
|
|
R&I
|
6,625
|
10
|
8
|
2,863
|
-
|
1,610
|
19
|
14
|
1,494
|
22
|
16
|
658
|
12
|
14
|
|
Beyfortus
|
147
|
(34)
|
(34)
|
84
|
(39)
|
-
|
-
|
-
|
61
|
(26)
|
(27)
|
2
|
(17)
|
(29)
|
|
FluMist
|
172
|
30
|
29
|
19
|
(3)
|
7
|
n/m
|
n/m
|
102
|
24
|
24
|
44
|
52
|
49
|
|
Other
ID
|
136
|
(38)
|
(41)
|
(1)
|
(38)
|
106
|
(34)
|
(38)
|
21
|
(43)
|
(48)
|
10
|
(60)
|
(57)
|
|
ID*
|
455
|
(21)
|
(22)
|
102
|
(34)
|
113
|
(30)
|
(34)
|
184
|
(9)
|
(10)
|
56
|
(1)
|
(2)
|
|
Ultomiris
|
4,016
|
16
|
16
|
2,190
|
12
|
306
|
73
|
73
|
915
|
19
|
14
|
605
|
11
|
16
|
|
Soliris
|
1,076
|
(25)
|
(26)
|
595
|
(30)
|
311
|
(5)
|
(7)
|
89
|
(44)
|
(47)
|
81
|
(24)
|
(23)
|
|
Strensiq
|
1,641
|
38
|
37
|
1,332
|
40
|
111
|
81
|
67
|
104
|
17
|
12
|
94
|
11
|
17
|
|
Koselugo
|
585
|
17
|
15
|
149
|
(5)
|
225
|
20
|
17
|
149
|
29
|
23
|
62
|
63
|
72
|
|
Other
Rare Disease
|
226
|
28
|
25
|
89
|
7
|
51
|
39
|
25
|
60
|
20
|
14
|
26
|
n/m
|
n/m
|
|
Rare Disease
|
7,544
|
12
|
11
|
4,355
|
9
|
1,004
|
27
|
24
|
1,317
|
11
|
6
|
868
|
11
|
16
|
|
Other Medicines
|
707
|
(5)
|
(6)
|
56
|
14
|
531
|
(6)
|
(8)
|
60
|
3
|
-
|
60
|
(14)
|
(12)
|
|
Total Medicines
|
43,962
|
7
|
5
|
17,851
|
4
|
12,289
|
7
|
3
|
9,948
|
15
|
9
|
3,874
|
4
|
7
|
The table provides an analysis of year-on-year Product Sales, with
Actual and CER growth rates reflecting year-on-year
growth.
* ID: Infectious Disease
Table
24: Product Sales year-on-year analysis: Q3 2026
|
For the quarter
|
World
|
US
|
Emerging Markets
|
Europe
|
Established RoW
|
|||||||||
|
ended 30 September
|
|
Change
|
|
Change
|
|
Change
|
|
Change
|
|
Change
|
||||
|
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
CER %
|
$m
|
Act %
|
CER %
|
|
Tagrisso
|
2,087
|
12
|
12
|
888
|
13
|
608
|
21
|
18
|
400
|
7
|
8
|
191
|
(8)
|
(1)
|
|
Imfinzi
|
1,990
|
24
|
26
|
1,120
|
23
|
229
|
36
|
35
|
429
|
25
|
27
|
212
|
19
|
29
|
|
Calquence
|
1,065
|
16
|
16
|
696
|
14
|
77
|
26
|
24
|
248
|
24
|
25
|
44
|
2
|
4
|
|
Lynparza
|
811
|
(3)
|
(3)
|
353
|
(3)
|
164
|
-
|
(2)
|
230
|
(5)
|
(4)
|
64
|
(3)
|
3
|
|
Enhertu
|
357
|
39
|
37
|
-
|
-
|
261
|
42
|
40
|
73
|
40
|
41
|
23
|
8
|
4
|
|
Zoladex
|
325
|
14
|
10
|
9
|
n/m
|
265
|
21
|
16
|
38
|
(5)
|
(5)
|
13
|
(41)
|
(42)
|
|
Truqap
|
210
|
9
|
9
|
144
|
(10)
|
20
|
n/m
|
n/m
|
32
|
83
|
85
|
14
|
56
|
66
|
|
Imjudo
|
103
|
23
|
25
|
57
|
4
|
20
|
n/m
|
n/m
|
15
|
17
|
21
|
11
|
5
|
11
|
|
Datroway
|
7
|
n/m
|
n/m
|
-
|
n/m
|
6
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
|
Etcamah
|
7
|
n/m
|
n/m
|
7
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
Oncology
|
108
|
2
|
3
|
3
|
64
|
74
|
7
|
5
|
4
|
(17)
|
(3)
|
27
|
(10)
|
-
|
|
Oncology
|
7,070
|
15
|
15
|
3,277
|
13
|
1,724
|
25
|
22
|
1,470
|
15
|
16
|
599
|
2
|
9
|
|
Farxiga
|
1,605
|
(25)
|
(25)
|
127
|
(71)
|
582
|
(35)
|
(37)
|
799
|
14
|
16
|
97
|
(5)
|
1
|
|
Crestor
|
332
|
9
|
6
|
9
|
(25)
|
300
|
15
|
11
|
-
|
n/m
|
n/m
|
23
|
(27)
|
(23)
|
|
Lokelma
|
219
|
16
|
17
|
75
|
(8)
|
56
|
55
|
50
|
49
|
41
|
43
|
39
|
8
|
15
|
|
Seloken
|
181
|
13
|
9
|
-
|
n/m
|
174
|
14
|
9
|
6
|
3
|
2
|
1
|
6
|
3
|
|
Brilinta
|
75
|
(48)
|
(50)
|
-
|
n/m
|
65
|
(1)
|
(5)
|
9
|
(61)
|
(60)
|
1
|
(51)
|
(45)
|
|
Wainua
|
68
|
16
|
17
|
61
|
11
|
1
|
(63)
|
(32)
|
5
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
|
roxadustat
|
21
|
(73)
|
(74)
|
-
|
-
|
21
|
(73)
|
(74)
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Baxfendy
|
9
|
n/m
|
n/m
|
9
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
CVRM
|
92
|
(36)
|
(34)
|
(2)
|
n/m
|
67
|
(3)
|
(4)
|
13
|
(70)
|
(68)
|
14
|
(4)
|
5
|
|
CVRM
|
2,602
|
(19)
|
(20)
|
279
|
(58)
|
1,266
|
(19)
|
(21)
|
881
|
9
|
11
|
176
|
(6)
|
-
|
|
Symbicort
|
666
|
(10)
|
(11)
|
227
|
(26)
|
236
|
5
|
2
|
129
|
(4)
|
(4)
|
74
|
(6)
|
(5)
|
|
Fasenra
|
602
|
13
|
14
|
355
|
8
|
57
|
n/m
|
95
|
131
|
7
|
8
|
59
|
18
|
25
|
|
Breztri
|
374
|
16
|
14
|
170
|
2
|
121
|
45
|
37
|
56
|
15
|
17
|
27
|
12
|
16
|
|
Tezspire
|
188
|
58
|
61
|
-
|
-
|
20
|
n/m
|
n/m
|
120
|
53
|
53
|
48
|
51
|
58
|
|
Saphnelo
|
235
|
31
|
32
|
198
|
27
|
7
|
94
|
88
|
21
|
60
|
66
|
9
|
29
|
38
|
|
Pulmicort
|
109
|
18
|
16
|
2
|
n/m
|
90
|
25
|
23
|
11
|
(9)
|
(10)
|
6
|
(32)
|
(22)
|
|
Airsupra
|
42
|
(7)
|
(4)
|
42
|
(3)
|
-
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Other
R&I
|
52
|
(3)
|
(3)
|
7
|
(43)
|
24
|
(2)
|
(4)
|
19
|
28
|
28
|
2
|
11
|
(12)
|
|
R&I
|
2,268
|
9
|
9
|
1,001
|
(1)
|
555
|
25
|
21
|
487
|
15
|
15
|
225
|
11
|
16
|
|
Beyfortus
|
76
|
(19)
|
(20)
|
23
|
(34)
|
-
|
-
|
-
|
52
|
(12)
|
(12)
|
1
|
-
|
-
|
|
FluMist
|
146
|
20
|
20
|
21
|
7
|
6
|
n/m
|
n/m
|
102
|
24
|
24
|
17
|
(11)
|
(7)
|
|
Other
ID
|
44
|
(24)
|
(25)
|
-
|
n/m
|
36
|
(8)
|
(12)
|
5
|
(54)
|
(52)
|
3
|
(65)
|
(55)
|
|
ID*
|
266
|
(3)
|
(3)
|
44
|
(19)
|
42
|
5
|
1
|
159
|
5
|
5
|
21
|
(24)
|
(22)
|
|
Ultomiris
|
1,432
|
17
|
19
|
792
|
15
|
116
|
82
|
86
|
310
|
14
|
16
|
214
|
7
|
15
|
|
Soliris
|
298
|
(35)
|
(35)
|
181
|
(34)
|
63
|
(38)
|
(37)
|
28
|
(40)
|
(42)
|
26
|
(29)
|
(27)
|
|
Strensiq
|
588
|
33
|
34
|
473
|
28
|
46
|
n/m
|
n/m
|
36
|
13
|
15
|
33
|
12
|
23
|
|
Koselugo
|
238
|
6
|
9
|
55
|
7
|
110
|
(2)
|
-
|
50
|
13
|
15
|
23
|
47
|
59
|
|
Other
Rare Disease
|
77
|
20
|
24
|
31
|
7
|
17
|
2
|
(1)
|
19
|
18
|
22
|
10
|
n/m
|
n/m
|
|
Rare Disease
|
2,633
|
9
|
10
|
1,532
|
8
|
352
|
15
|
17
|
443
|
8
|
9
|
306
|
8
|
16
|
|
Other Medicines
|
227
|
(2)
|
(3)
|
14
|
48
|
172
|
-
|
(1)
|
21
|
(9)
|
(13)
|
20
|
(30)
|
(24)
|
|
Total Medicines
|
15,066
|
5
|
5
|
6,147
|
2
|
4,111
|
5
|
3
|
3,461
|
12
|
13
|
1,347
|
2
|
9
|
The table provides an analysis of year-on-year Product Sales, with
Actual and CER growth rates reflecting year-on-year
growth.
* ID: Infectious Disease
Table
25: Alliance Revenue: 9M 2026
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
Enhertu
|
1,670
|
1,291
|
|
Tezspire
|
614
|
453
|
|
Beyfortus
|
279
|
252
|
|
Datroway
|
164
|
38
|
|
Other
royalty revenue
|
76
|
70
|
|
Other
Alliance Revenue
|
3
|
4
|
|
Total
|
2,806
|
2,108
|
Table
26: Collaboration Revenue: 9M 2026
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
Farxiga: sales milestones
|
80
|
81
|
|
Crestor: sales milestones
|
32
|
-
|
|
Other
Collaboration Revenue
|
1
|
12
|
|
Total
|
113
|
93
|
Table
27: Other operating income and expense: 9M 2026
|
For the nine
months ended 30
September
|
2026
$m
|
2025
$m
|
|
Disposal
of Zoryve interest
|
100
|
-
|
|
Other
|
518
|
281
|
|
Total
|
618
|
281
|
Other
shareholder information
Financial
calendar
–
Announcement of FY
and Q4 2026 results: 9 February 2027
Dividend
payment dates
Dividends are
normally paid as follows:
–
First
interim: Announced with the half-year results and paid in
September
–
Second interim:
Announced with the full-year results and paid in March
Contact
details
For
Investor Relations contacts, click
here. For Media contacts, click
here.
Addresses
for correspondence
|
Registered office
|
UK Registrar and Transfer Office
|
Swedish Central Securities Depository
|
US Registrar and Transfer Agent
|
|
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2
0AA
|
Computershare
Investor Services PLC
The
Pavilions
Bridgwater
Road
Bristol
BS99
6ZZ
|
Euroclear
Sweden AB
PO Box
191
SE-101
23 Stockholm
|
Computershare
Investor Services
PO Box
43078
Providence
RI,
02940-3078
|
|
UK
|
UK
|
Sweden
|
US
|
|
+44 (0)
20 3749 5000
|
0800
707 1682 (UK only)
|
+46 (0)
8 402 9000
|
+1
(888) 697 8018 (US only)
|
|
|
+44 (0)
370 707 1682
|
|
+1
(781) 575 2844
|
Trademarks
Trademarks
of the AstraZeneca group of companies appear throughout this
document in italics. Medical publications also appear throughout
the document in italics. AstraZeneca, the AstraZeneca logotype and
the AstraZeneca symbol are all trademarks of the AstraZeneca group
of companies. Trademarks of companies other than AstraZeneca that
appear in this document include: Beyfortus, a trademark of Sanofi
Pasteur Inc.; Enhertu and
Datroway, trademarks of
Daiichi Sankyo; Seloken,
owned by AstraZeneca or Taiyo Pharma Co., Ltd (depending on
geography); Synagis, owned
by AstraZeneca or Sobi aka Swedish Orphan Biovitrum AB (publ)
(depending on geography); Tezspire, a trademark of Amgen, Inc;
and Zoryve a trademark of Arcutis Biotherapeutics,
Inc.
Information
on or accessible through AstraZeneca's websites, including
astrazeneca.com, does not form
part of and is not incorporated into this
announcement.
AstraZeneca
AstraZeneca
(LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and
commercialisation of prescription medicines in Oncology, Rare
Diseases, and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca’s innovative medicines are sold in
more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com
and follow the Company on Social Media @AstraZeneca.
Cautionary statements regarding forward-looking
statements
In
order, among other things, to utilise the 'safe harbour' provisions
of the US Private Securities Litigation Reform Act of 1995,
AstraZeneca (hereafter 'the Group') provides the following
cautionary statement:
This
document contains certain forward-looking statements with respect
to the operations, performance and financial condition of the
Group, including, among other things, statements about expected
revenues, margins, earnings per share or other financial or other
measures. Although the Group believes its expectations are based on
reasonable assumptions, any forward-looking statements, by their
very nature, involve risks and uncertainties and may be influenced
by factors that could cause actual outcomes and results to be
materially different from those predicted. The forward-looking
statements reflect knowledge and information available at the date
of preparation of this document and the Group undertakes no
obligation to update these forward-looking statements. The Group
identifies the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar
expressions in such statements. Important factors that could cause
actual results to differ materially from those contained in
forward-looking statements, certain of which are beyond the Group's
control, include, among other things:
– the risk of
failure or delay in delivery of the pipeline or launch of new
medicines
– the risk of
failure to meet regulatory or ethical requirements for medicine
development or approval
– the risk of
failures or delays in the quality or execution of the Group’s
commercial strategies
– the risk of
pricing, affordability, access and competitive
pressures
– the risk of
failure to maintain supply of compliant, quality
medicines
– the risk of
illegal trade in the Group’s medicines
– the risk of
reliance on third-party goods and services
– the risk of
failure in IT or cybersecurity
– the risk of
failure of critical processes
– the risk of
failure to collect and manage data and AI in line with legal and
regulatory requirements and strategic objectives
– the risk of
failure to attract, develop, engage and retain a diverse, talented
and capable workforce
– the risk of
failure to meet sustainability targets, regulatory requirements or
stakeholder expectations with respect to the
environment
– the risk of
failure to meet regulatory and ethical expectations on commercial
practices, including anti-bribery/anti-corruption, anti-fraud and
scientific exchanges
– the risk of
the safety and efficacy of marketed medicines being
questioned
– the risk of
adverse outcome of litigation and/or governmental
investigations
– intellectual
property-related risks to the Group’s products
– the risk of
failure to achieve strategic plans or meet targets or
expectations
– the risk of
geopolitical and/or macroeconomic volatility disrupting the
operation of the Group’s global business
– the risk of failure
in internal control, financial reporting or the occurrence of
fraud
– the risk of
unexpected deterioration in the Group’s financial
position.
Glossary
1L, 2L,
etc
First line, second line,
etc
6MWT
Six-minute walk test
ADC
Antibody drug
conjugate
aHUS
Atypical haemolytic uraemic
syndrome
AI
Aromatase
inhibitors
AL
Amyloid
light chain
ANDA
Abbreviated New Drug Application
(US)
ASBMR
American Society for Bone and Mineral
Research
ATTR /
-CM / -PN
Transthyretin-mediated amyloid / cardiomyopathy /
polyneuropathy
BC
Breast
cancer
BCG
Bacillus
Calmette-Guérin therapy
BPI-SF
Brief Pain Inventory - Short
Form
BRCA /
m / wt
Breast cancer gene / mutation / wild-type
BTK
Bruton tyrosine
kinase
CDK4,
CDK6
Cyclin-dependent kinase 4 / 6
CER
Constant exchange
rates
CHMP
Committee for Medicinal Products
for Human Use (EU)
CI
Confidence
interval
CLDN-18
Claudin-18
CLL
Chronic lymphocytic
leukaemia
CN
China
COPD
Chronic obstructive pulmonary
disease
CRSwNP
Chronic rhinosinusitis with nasal polyps
CV
Cardiovascular
CVRM
Cardiovascular, Renal and
Metabolism
DSQ
Dysphagia Symptom
Questionnaire
EBITDA
Reported Profit before tax after adding back
Net finance expense, results from joint ventures and associates,
and charges for Depreciation, amortisation and
impairment
EFS
Event-free
survival
EGFR /
m
Epidermal growth factor receptor gene /
mutation
EGPA
Eosinophilic granulomatosis with
polyangiitis
EPS
Earnings per
share
ER
Oestrogen
receptor
ERS
European Respiratory
Society
ESC
European Society of
Cardiology
ESMO
European Society for Medical
Oncology
ESR1 /
m
Oestrogen Receptor 1 gene /
mutation
ES-SCLC
Extensive stage small cell lung
cancer
EU
Europe (in
financial tables) or European Union
EVH
Extravascular
haemolysis
FDA
US Food and Drug
Administration
FDC
Fixed dose
combination
FY
Full year /
Financial year
GAAP
Generally Accepted Accounting
Principles
GAAP
Generally Accepted Accounting
Principles
GEJ
Gastro oesophageal
junction
GI
Gastrointestinal
gMG
Generalised myasthenia
gravis
GU
Genito-urinary
GYN
Gynaecological
HER2 /
+/- /low /m Human epidermal growth
factor receptor 2 gene / positive / negative / low expression /
mutant
HES
Hypereosinophilic
syndrome
HPP
Hypophosphatasia
HR / +
/ -
Hormone receptor / positive /
negative
HRD
Homologous recombination
deficiency
HSCT-TMA
Hematopoietic stem cell transplantation-associated thrombotic
microangiopathy
HSPC
Hormone-sensitive prostate
cancer
IAS /
B
International Accounting
Standards / Board
IASLC
International Association for the Study
of Lung Cancer
ICS
Inhaled
corticosteroid
ID
Infectious
Disease
IDMC
Independent Data Monitoring
Committee
IFRS
International Financial
Reporting Standards
IgAN
Immunoglobulin A
nephropathy
IHC
Immunohistochemistry
IL-5,
IL-33, etc
Interleukin-5, interleukin-33, etc
JP
Japan
LABA
Long-acting beta-2 agonist
LAMA
Long-acting muscarinic-antagonist
LOE
Loss of exclusivity
m
Metastatic (e.g. mBTC , mCRPC)
MASH
Metabolic dysfunction-associated
steatohepatitis
MCL
Mantle cell lymphoma
MET
Mesenchymal-epithelial
transition
MIBC
Muscle-invasive bladder
cancer
n/m
Growth rate not
meaningful
NGP
Next-generation
propellant
NME
New molecular entity
NMIBC
Non muscle-invasive bladder cancer
NMOSD
Neuromyelitis optica spectrum disorder
NRDL
National reimbursement drug list
NSCLC
Non-small cell lung cancer
o Oral
(e.g. oGLP1, oPCSK9)
OS
Overall
survival
PARP /
i / -1sel
Poly ADP ribose polymerase / inhibitor /
-1
selective
PD-1
Programmed cell death protein
1
PD-L1
Programmed death-ligand 1
PFS
Progression-free
survival
PNH
Paroxysmal nocturnal
haemoglobinuria
PR
Partial
response
PTEN
Phosphatase and tensin homologue
gene
R&I
Respiratory &
Immunology
RR
Relative
reduction
SEC
Securities Exchange Commission
(US)
SG&A
Sales, general and
administration
TKI
Tyrosine kinase
inhibitor
TNBC
Triple negative breast cancer
UEGW
United European Gastroenterology
Week
VBP
Volume-based
procurement
VEGF
Vascular endothelial growth
factor
WCLC
World Conference on Lung Cancer
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly
authorized.
|
|
AstraZeneca PLC
|
Date: 30 October
2026
|
|
By: /s/ Matthew Bowden
|
|
|
Name: Matthew Bowden
|
|
|
Title: Company Secretary
|